#LCSM Transcript

Healthcare social media transcript of the #LCSM hashtag.
().
See #LCSM Influencers/Analytics.

ProfileTweet
Charu Aggarwal, MD, MPH @CharuAggarwalMD
Hi everyone! Looking forward to tonight's #LCSMchat I am a medical oncologist @PennCancer @PennMedicine #LCSM @lcsmchat
Danielle Pardue @Actorielle
Good evening, friends! Excited to be together. Looked forward to this all day. 💚 #lcsm
Janet Freeman-Daily @JFreemanDaily
Welcome to #LCSM Chat! Tonight’s chat will discuss “Liquid Bx—It pays to be vein.” (Bx=biopsy) More info on our blog at https://t.co/0hz3jRwX1g
Danielle Pardue @Actorielle
RT @JFreemanDaily: Welcome to #LCSM Chat! Tonight’s chat will discuss “Liquid Bx—It pays to be vein.” (Bx=biopsy) More info on our blog at https://t.co/0hz3jRwX1g
Upstage Lung Cancer @UpstageLungCanc
RT @JFreemanDaily: Welcome to #LCSM Chat! Tonight’s chat will discuss “Liquid Bx—It pays to be vein.” (Bx=biopsy) More info on our blog at https://t.co/0hz3jRwX1g
Janet Freeman-Daily @JFreemanDaily
I’m your moderator Janet Freeman-Daily: writer (https://t.co/OBCc87ZwkG), science geek, stage IV #lungcancer patient and research advocate. I will be joined by TWO special guests! #lcsm
Faces of Lung Cancer 🇺🇦 @LungCancerFaces
Deana Hendrickson in sunny Los Angeles here. I’ll be tweeting from the @lcsmchat account tonight during #LCSM Chat. We’re about to start. Join us! https://t.co/Tp4hiLHVe2
OncLive SOSS @OncLiveSOSS
LISTEN: John V. Heymach, MD, PhD, of @MDAndersonNews, discusses the incidence of EGFR exon 20 insertions in lung cancer, and diagnostic challenges of identifying EGFR exon 20 insertions #lcsm https://t.co/5TkhcvqOd2 https://t.co/Fg3ac0pczt
Jill Feldman @jillfeldman4
Hi All, looking forward to tonight's chat, although will be multitasking because @KUHoops is playing #RCJH #LCSM
Upstage Lung Cancer @UpstageLungCanc
Happy Thursday, friends! Always an honor to be here. #lcsm
GYN Cancer | #GYNCSM @gyncsm
RT @AdvocateCollab: Advocates: Advocates: It's been a helluva year. What have we learned about Cancer & COVID19 in the past year? What do we still want/need to know? Registration to the #CCC19 retreat is open, please consider attending https://t.co/IUznen53es #OncoAlert #bcsm #btsm #gyncsm #lcsm #crcsm #mmsm
Gia Sonata @RedGia
RT @JFreemanDaily: Welcome to #LCSM Chat! Tonight’s chat will discuss “Liquid Bx—It pays to be vein.” (Bx=biopsy) More info on our blog at https://t.co/0hz3jRwX1g
Janet Freeman-Daily @JFreemanDaily
RT @IASLC: Listen March 8 for a special edition of #LungCancerConsidered @StephenVLiu & co-host Paul Bunn are joined by, Dr. Tal Zaks, CMO at @moderna_tx & @acmoorephd. They discuss the development of the Moderna #COVID-19 vaccine. https://t.co/g50D8L1NAm #LCSM @HwakeleeMD @NarjustDumaMD https://t.co/eL0BfS797Z
Erika Hlavacek @ErikaHlavacek
Good Evening #lcsm chatters from Chicago❤️
Kristin Ito @KAdvocate_LCAM
Warm hello from chilly Denver @lcsmchat Looking forward to tonight's discussion! #LCSM
Danielle Pardue @Actorielle
RT @LungCancerFaces: Deana Hendrickson in sunny Los Angeles here. I’ll be tweeting from the @lcsmchat account tonight during #LCSM Chat. We’re about to start. Join us! https://t.co/Tp4hiLHVe2
Janet Freeman-Daily @JFreemanDaily
Charu Aggarwal, MD, MPH, (@CharuAggarwalMD) is the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at Penn Medicine. https://t.co/tQ7zWYeGn2 #lcsm
Lecia Sequist, MD, MPH @LeciaSequist
@CharuAggarwalMD @PennCancer @PennMedicine @lcsmchat Hi everyone! So happy to be here tonight with my friend @CharuAggarwalMD I am medical oncologist @MGHCancerCenter @MGHThoracicOnc #LCSM
#LCSM Chat @lcsmchat
@Actorielle Hey lady! #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: Welcome to #LCSM Chat! Tonight’s chat will discuss “Liquid Bx—It pays to be vein.” (Bx=biopsy) More info on our blog at https://t.co/0hz3jRwX1g
Janet Freeman-Daily @JFreemanDaily
Lecia Sequist, MD, MPH, (@LeciaSequist) is the Landry Family Professor of Medicine at Harvard Medical School and the Director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital. https://t.co/fzqQxKbUwg #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: I’m your moderator Janet Freeman-Daily: I’m your moderator Janet Freeman-Daily: writer (https://t.co/OBCc87ZwkG), science geek, stage IV #lungcancer patient and research advocate. I will be joined by TWO special guests! #lcsm
Sara Whitlock @sjwhitlock
Hello from Dayton, Ohio !#LCSM
Erika Hlavacek @ErikaHlavacek
RT @LungCancerFaces: Deana Hendrickson in sunny Los Angeles here. I’ll be tweeting from the @lcsmchat account tonight during #LCSM Chat. We’re about to start. Join us! https://t.co/Tp4hiLHVe2
Janet Freeman-Daily @JFreemanDaily
We'll get started in a few minutes -- please take a moment to introduce yourselves #lcsm
kristen kimball @KimballKristen
Kris (Kimball) from Boston here, excited about tonight's topic. Thank you! #LCSM
#LCSM Chat @lcsmchat
@jillfeldman4 @KUHoops Hi Jill! #lcsm
#LCSM Chat @lcsmchat
@UpstageLungCanc Welcome! #lcsm
Gia Sonata @RedGia
Gia here from NC. Stage IV lung cancer since 9/2014. Looking forward to this discussion. #lcsm
#LCSM Chat @lcsmchat
@ErikaHlavacek Hi Erika! #lcsm
Triage Cancer @TriageCancer
Excited to join tonight! We're a national nonprofit that provides free educational/informational resources about the legal and practical issues that can affect someone after a #cancer diagnosis. Always eager to learn from this group! #lcsm
#LCSM Chat @lcsmchat
@KAdvocate_LCAM Hey Kristin! #lcsm
Janet Freeman-Daily @JFreemanDaily
If you are new to Twitter chats and/or #LCSM Chat, you might find our primer on how to participate helpful https://t.co/5g28sSQQLb
#LCSM Chat @lcsmchat
RT @JFreemanDaily: Charu Aggarwal, MD, MPH, (@CharuAggarwalMD) is the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at Penn Medicine. https://t.co/tQ7zWYeGn2 #lcsm
B @B32598085
Hello from Ontario, Canada #LCSM
#LCSM Chat @lcsmchat
RT @JFreemanDaily: Lecia Sequist, MD, MPH, (@LeciaSequist) is the Landry Family Professor of Medicine at Harvard Medical School and the Director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital. https://t.co/fzqQxKbUwg #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BSBreastCancer: Who's joining in for the #LCSM Chat tonight? All Cancers Chat #bcsm #btsm #ayacsm #gyncsm #orosm #Pcsm @LizSzabo
Danielle Pardue @Actorielle
RT @LeciaSequist: @CharuAggarwalMD @PennCancer @PennMedicine @lcsmchat Hi everyone! So happy to be here tonight with my friend @CharuAggarwalMD I am medical oncologist @MGHCancerCenter @MGHThoracicOnc #LCSM
Dave Bjork @bjork5
Hi friends, Dave Bjork here in Boston, host of the https://t.co/WePGnEdkmc #LCSM
#LCSM Chat @lcsmchat
@sjwhitlock Hello Sara! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: Hi everyone! Looking forward to tonight's #LCSMchat I am a medical oncologist @PennCancer @PennMedicine #LCSM @lcsmchat
#LCSM Chat @lcsmchat
RT @JFreemanDaily: We'll get started in a few minutes -- please take a moment to introduce yourselves #lcsm
Matthew Smeltzer @MattSmeltzer
Hi Everyone! This is Matt, from Memphis. #LCSM
Danielle Pardue @Actorielle
RT @JFreemanDaily: Lecia Sequist, MD, MPH, (@LeciaSequist) is the Landry Family Professor of Medicine at Harvard Medical School and the Director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital. https://t.co/fzqQxKbUwg #lcsm
#LCSM Chat @lcsmchat
@KimballKristen Hi Kris! #lcsm
#LCSM Chat @lcsmchat
@RedGia Hey Gia! #lcsm
Danielle Pardue @Actorielle
RT @JFreemanDaily: If you are new to Twitter chats and/or #LCSM Chat, you might find our primer on how to participate helpful https://t.co/5g28sSQQLb
Charu Aggarwal, MD, MPH @CharuAggarwalMD
#LCSM @lcsmchat
Dave Bjork @bjork5
She is awesome! #lcsm
Upstage Lung Cancer @UpstageLungCanc
RT @TriageCancer: Excited to join tonight! We're a national nonprofit that provides free educational/informational resources about the legal and practical issues that can affect someone after a #cancer diagnosis. Always eager to learn from this group! #lcsm
#LCSM Chat @lcsmchat
@TriageCancer Welcome! #lcsm
Eric Bernicker @EricBernicker
Greetings from Houston where we have power, clean water and ...fewer masks 😗 I am a thoracic medical oncologist. #LCSM
#LCSM Chat @lcsmchat
RT @JFreemanDaily: If you are new to Twitter chats and/or #LCSM Chat, you might find our primer on how to participate helpful https://t.co/5g28sSQQLb
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@ChristianRolfo @JFreemanDaily @UMmedschool @isliquidbiopsy @LeciaSequist Good to see you Christian! #LCSM
Upstage Lung Cancer @UpstageLungCanc
RT @JFreemanDaily: If you are new to Twitter chats and/or #LCSM Chat, you might find our primer on how to participate helpful https://t.co/5g28sSQQLb
Deb Smith 🌻 @debsmithbeach
Hi, Deb here from chilly, blustery NH. I had stable scans on 2/5 and my first Covid vaccination on 2/24!! Thanks to science, medical research, clinical trials, and luck, I’ve lived 9 1/2 yrs with stage 4 LC. I’ll get to see my son again soon! #LCSM
Nathan A. Pennell MD, PhD, FASCO @n8pennell
Nate Pennell in Cleveland! #lcsm
#LCSM Chat @lcsmchat
@B32598085 Welcome! Thanks for joining. #lcsm
#LCSM Chat @lcsmchat
@bjork5 Hey Dave! #lcsm
kristen kimball @KimballKristen
RT @JFreemanDaily: Lecia Sequist, MD, MPH, (@LeciaSequist) is the Landry Family Professor of Medicine at Harvard Medical School and the Director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital. https://t.co/fzqQxKbUwg #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
Liquid biopsies are a valuable tool in the therapeutic management in #NSCLC. We now have 2 @FDAOncology approved assays for use in the clinic to maximize our ability to detect mutations @GuardantHealth @FoundationATCG #LCSM https://t.co/Z7NGwXy9yj
kristen kimball @KimballKristen
RT @JFreemanDaily: Welcome to #LCSM Chat! Tonight’s chat will discuss “Liquid Bx—It pays to be vein.” (Bx=biopsy) More info on our blog at https://t.co/0hz3jRwX1g
#LCSM Chat @lcsmchat
@MattSmeltzer Hi Matt! Welcome. #lcsm
Jill Feldman @jillfeldman4
RT @CharuAggarwalMD: Liquid biopsies are a valuable tool in the therapeutic management in #NSCLC. We now have 2 @FDAOncology approved assays for use in the clinic to maximize our ability to detect mutations @GuardantHealth @FoundationATCG #LCSM https://t.co/Z7NGwXy9yj
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@n8pennell Hi Nate! #LCSM
Upstage Lung Cancer @UpstageLungCanc
RT @CharuAggarwalMD: Liquid biopsies are a valuable tool in the therapeutic management in #NSCLC. We now have 2 @FDAOncology approved assays for use in the clinic to maximize our ability to detect mutations @GuardantHealth @FoundationATCG #LCSM https://t.co/Z7NGwXy9yj
Janet Freeman-Daily @JFreemanDaily
Please remember to use #lcsm in all your tweets so others participating in the chat can see them.
Adrian Sacher, M.D. @DocSacher
RT @OncLive: Poziotinib Shows Meaningful Activity in EGFR Exon 20–Mutant NSCLC @DocSacher @pmcancercentre #lcsm https://t.co/9RsBmZhl6h
Patty Watkins @Pattybeatslungc
RT @CharuAggarwalMD: Liquid biopsies are a valuable tool in the therapeutic management in #NSCLC. We now have 2 @FDAOncology approved assays for use in the clinic to maximize our ability to detect mutations @GuardantHealth @FoundationATCG #LCSM https://t.co/Z7NGwXy9yj
#LCSM Chat @lcsmchat
@EricBernicker Hi Eric! We’ll have to compare our fave Dead songs one day. #lcsm
Janet Freeman-Daily @JFreemanDaily
If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience. However, if you want to jump in, feel free -- we're a friendly bunch!
Luis E Raez @LuisERaez1
RT @CharuAggarwalMD: Liquid biopsies are a valuable tool in the therapeutic management in #NSCLC. We now have 2 @FDAOncology approved assays for use in the clinic to maximize our ability to detect mutations @GuardantHealth @FoundationATCG #LCSM https://t.co/Z7NGwXy9yj
Triage Cancer @TriageCancer
RT @CharuAggarwalMD: Liquid biopsies are a valuable tool in the therapeutic management in #NSCLC. We now have 2 @FDAOncology approved assays for use in the clinic to maximize our ability to detect mutations @GuardantHealth @FoundationATCG #LCSM https://t.co/Z7NGwXy9yj
Janet Freeman-Daily @JFreemanDaily
Note: Twitter allows tweets up to 280 characters, but some tweetchat apps (like https://t.co/A2M7gXQ66L) will not display tweets longer than 140. #lcsm
#LCSM Chat @lcsmchat
Welcome! Remember to include the hashtag #lcsm in all your tweets so we can see them during the chat.
Kristin Ito @KAdvocate_LCAM
RT @JFreemanDaily: Please remember to use #lcsm in all your tweets so others participating in the chat can see them.
Erika Hlavacek @ErikaHlavacek
RT @CharuAggarwalMD: Liquid biopsies are a valuable tool in the therapeutic management in #NSCLC. We now have 2 @FDAOncology approved assays for use in the clinic to maximize our ability to detect mutations @GuardantHealth @FoundationATCG #LCSM https://t.co/Z7NGwXy9yj
Nirmal Raut @oncologician
RT @LeciaSequist: I'm excited about #LCSM chat tonight! The wonderful @CharuAggarwalMD and I will be discussing liquid biopsies. Starting in a few minutes! Come join us. Thank you @JFreemanDaily for the invitation!
#LCSM Chat @lcsmchat
@debsmithbeach Yay! Great news, Deb. #lcsm
Eric Bernicker @EricBernicker
Absolutely!
#LCSM Chat @lcsmchat
@n8pennell Hi Nate! #lcsm
Danielle Pardue @Actorielle
RT @CharuAggarwalMD: Liquid biopsies are a valuable tool in the therapeutic management in #NSCLC. We now have 2 @FDAOncology approved assays for use in the clinic to maximize our ability to detect mutations @GuardantHealth @FoundationATCG #LCSM https://t.co/Z7NGwXy9yj
Charu Aggarwal, MD, MPH @CharuAggarwalMD
#LCSM @lcsmchat
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: Liquid biopsies are a valuable tool in the therapeutic management in #NSCLC. We now have 2 @FDAOncology approved assays for use in the clinic to maximize our ability to detect mutations @GuardantHealth @FoundationATCG #LCSM https://t.co/Z7NGwXy9yj
Janet Freeman-Daily @JFreemanDaily
#LCSM
#LCSM Chat @lcsmchat
RT @JFreemanDaily: Please remember to use #lcsm in all your tweets so others participating in the chat can see them.
Nirmal Raut @oncologician
RT @JFreemanDaily: Welcome to #LCSM Chat! Tonight’s chat will discuss “Liquid Bx—It pays to be vein.” (Bx=biopsy) More info on our blog at https://t.co/0hz3jRwX1g
#LCSM Chat @lcsmchat
RT @JFreemanDaily: If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience. However, if you want to jump in, feel free -- we're a friendly bunch!
#LCSM Chat @lcsmchat
RT @JFreemanDaily: Note: Note: Twitter allows tweets up to 280 characters, but some tweetchat apps (like https://t.co/A2M7gXQ66L) will not display tweets longer than 140. #lcsm
kristen kimball @KimballKristen
@debsmithbeach #LCSM I'm glad to hear this, Deb :)
Christian Rolfo @ChristianRolfo
@CharuAggarwalMD @lcsmchat Sorry I forgot #LCSM !
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: #LCSM @lcsmchat
Janet Freeman-Daily @JFreemanDaily
I will announce FOUR topics (T1 T2 etc). Pls label your answers with T1, T2, etc to make transcript easier to follow. #lcsm
Mia Spano-Curtiss & Sondra Price @BSBreastCancer
RT @RedGia: Gia here from NC. Stage IV lung cancer since 9/2014. Looking forward to this discussion. #lcsm
#LCSM Chat @lcsmchat
@CharuAggarwalMD We still love you. #lcsm
Janet Freeman-Daily @JFreemanDaily
T1. What are the different methods of liquid biopsy (liquid Bx)? What are the advantages and pitfalls of each? #lcsm
Renee Parker @Traveldoc33
@JFreemanDaily @lcsmchat #LCSM First time participant. Looking forward to it. I am a retired OB/GYN thanks to lung cancer and now am a patient advocate.
Lecia Sequist, MD, MPH @LeciaSequist
T1: @CharuAggarwalMD will tell you about ctDNA, which is in clinical use already. I'll tell you about some other types of liquid biopsies that aren't yet ready for prime time. also note there are hundreds of diff technological platforms, each with unique pro's and con's #LCSM
Lecia Sequist, MD, MPH @LeciaSequist
T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu
#LCSM Chat @lcsmchat
RT @JFreemanDaily: #LCSM
#LCSM Chat @lcsmchat
RT @JFreemanDaily: I will announce FOUR topics (T1 T2 etc). Pls label your answers with T1, T2, etc to make transcript easier to follow. #lcsm
Luis E Raez @LuisERaez1
Agree and also i think they are many more potential indications of liquid biopsies than doing molecular dx for metastatic disease, we need to move to: monitor response, detection of recurrence and ultimately cancer diagnosis. @isliquidbiopsy @FLASCO_ORG @MCIStrong @mhshospital
Jill Feldman @jillfeldman4
RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T1. What are the different methods of liquid biopsy (liquid Bx)? What are the advantages and pitfalls of each? #lcsm
Erika Hlavacek @ErikaHlavacek
RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu
#LCSM Chat @lcsmchat
@Traveldoc33 @JFreemanDaily Hey Renee! Welcome. #lcsm
Peggy Dennis @peggyddennis
Peggy joining from Denver. Hi all! #lcsm
#LCSM Chat @lcsmchat
RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu
#LCSM Chat @lcsmchat
RT @LeciaSequist: T1: T1: @CharuAggarwalMD will tell you about ctDNA, which is in clinical use already. I'll tell you about some other types of liquid biopsies that aren't yet ready for prime time. also note there are hundreds of diff technological platforms, each with unique pro's and con's #LCSM
Mia Spano-Curtiss & Sondra Price @BSBreastCancer
#LCSM Mia from #BSBC here! Good evening everyone thanks @RedGia for the invite!
Lecia Sequist, MD, MPH @LeciaSequist
@ChristianRolfo @CharuAggarwalMD @FDAOncology @GuardantHealth @FoundationATCG This paradigm plays out over and over across oncology.... #LCSM
Nathan A. Pennell MD, PhD, FASCO @n8pennell
RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu
Charu Aggarwal, MD, MPH @CharuAggarwalMD
RT @LeciaSequist: T1: T1: @CharuAggarwalMD will tell you about ctDNA, which is in clinical use already. I'll tell you about some other types of liquid biopsies that aren't yet ready for prime time. also note there are hundreds of diff technological platforms, each with unique pro's and con's #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
T1. The most commonly used “#LiquidBiopsy” approach in clinical practice today relies on analysis of circulating tumor DNA, “shed” fragments of tumor DNA that can be extracted from blood, amplified and analyzed #LCSM
Lecia Sequist, MD, MPH @LeciaSequist
T1: In lung cancer, CTCs are especially prevalent in SCLC and have been used to make patient-derived models by @AnnaFaragoMD @LaurenByersMD and other groups too #LCSM https://t.co/8oPlb43fmQ https://t.co/gkDm8Nd1Bu
Lecia Sequist, MD, MPH @LeciaSequist
T1: Circulating tumor cells (CTCs) are rare, whole cells that break off from a cancer and can be captured by a variety of methods in the blood. While CTCs have not yet made it to clinical use, their potential as a modality for discovery re: cancer biology is large #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu
#LCSM Chat @lcsmchat
@peggyddennis Hi Peggy! #lcsm
Janet Freeman-Daily @JFreemanDaily
@LeciaSequist What are CTCs, ctDNA, exosomes and RNA? #LCSM
#LCSM Chat @lcsmchat
@BSBreastCancer @RedGia Welcome! So glad you’ve joined us. #lcsm
Mia Spano-Curtiss & Sondra Price @BSBreastCancer
#LCSM #LiquidBiopsy #cancer
Erika Hlavacek @ErikaHlavacek
RT @LeciaSequist: T1: T1: Circulating tumor cells (CTCs) are rare, whole cells that break off from a cancer and can be captured by a variety of methods in the blood. While CTCs have not yet made it to clinical use, their potential as a modality for discovery re: cancer biology is large #LCSM
Sophia Kamran, MD @sophia_kamran
RT @HenningWillers: @dr_jonathant @DrChowdharyMD @XRT4U @SorenBentzen 1/n Yeah that data may go in a similar direction. Ok so here is what we are thinking regarding optimal esophagus sparing with IMRT and the question of BID vs QD ... Presented by @sophia_kamran at #ASTRO20 @ASTRO_org https://t.co/C9FFnHQFmo Paper will come out next month
Charu Aggarwal, MD, MPH @CharuAggarwalMD
T1. Circulating tumor DNA (#ctDNA) is tumor-derived fragmented DNA in the bloodstream cell-free DNA (cfDNA) is a broader term which describes DNA that is freely circulating in the bloodstream, but is not necessarily of tumor origin #LCSM
Lecia Sequist, MD, MPH @LeciaSequist
T1: Exosomes are tiny packets of intracellular material that pinch away from the cancer cell, surrounded by bubble-like membrane. They can contain bits of DNA, RNA, proteins, and may be one of the ways cells "talk" to each other #LCSM
#LCSM Chat @lcsmchat
RT @LeciaSequist: T1: T1: Circulating tumor cells (CTCs) are rare, whole cells that break off from a cancer and can be captured by a variety of methods in the blood. While CTCs have not yet made it to clinical use, their potential as a modality for discovery re: cancer biology is large #LCSM
Mia Spano-Curtiss & Sondra Price @BSBreastCancer
#LCSM
kristen kimball @KimballKristen
RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: T1. The most commonly used “#LiquidBiopsy” approach in clinical practice today relies on analysis of circulating tumor DNA, “shed” fragments of tumor DNA that can be extracted from blood, amplified and analyzed #LCSM
#LCSM Chat @lcsmchat
RT @LeciaSequist: T1: T1: In lung cancer, CTCs are especially prevalent in SCLC and have been used to make patient-derived models by @AnnaFaragoMD @LaurenByersMD and other groups too #LCSM https://t.co/8oPlb43fmQ https://t.co/gkDm8Nd1Bu
Denise Cutlip @dennycee
@lcsmchat @peggyddennis Hi, Peggy. Happy to see you. #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @LeciaSequist What are CTCs, ctDNA, exosomes and RNA? #LCSM
Jill Feldman @jillfeldman4
RT @LeciaSequist: T1: T1: In lung cancer, CTCs are especially prevalent in SCLC and have been used to make patient-derived models by @AnnaFaragoMD @LaurenByersMD and other groups too #LCSM https://t.co/8oPlb43fmQ https://t.co/gkDm8Nd1Bu
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: T1. Circulating tumor DNA (#ctDNA) is tumor-derived fragmented DNA in the bloodstream cell-free DNA (cfDNA) is a broader term which describes DNA that is freely circulating in the bloodstream, but is not necessarily of tumor origin #LCSM
Mia Spano-Curtiss & Sondra Price @BSBreastCancer
#LCSM
#LCSM Chat @lcsmchat
RT @LeciaSequist: T1: T1: Exosomes are tiny packets of intracellular material that pinch away from the cancer cell, surrounded by bubble-like membrane. They can contain bits of DNA, RNA, proteins, and may be one of the ways cells "talk" to each other #LCSM
Jill Feldman @jillfeldman4
RT @CharuAggarwalMD: T1. Circulating tumor DNA (#ctDNA) is tumor-derived fragmented DNA in the bloodstream cell-free DNA (cfDNA) is a broader term which describes DNA that is freely circulating in the bloodstream, but is not necessarily of tumor origin #LCSM
Erika Hlavacek @ErikaHlavacek
RT @CharuAggarwalMD: T1. Circulating tumor DNA (#ctDNA) is tumor-derived fragmented DNA in the bloodstream cell-free DNA (cfDNA) is a broader term which describes DNA that is freely circulating in the bloodstream, but is not necessarily of tumor origin #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: T1: T1: @CharuAggarwalMD will tell you about ctDNA, which is in clinical use already. I'll tell you about some other types of liquid biopsies that aren't yet ready for prime time. also note there are hundreds of diff technological platforms, each with unique pro's and con's #LCSM
Denise Cutlip @dennycee
RT @JFreemanDaily: @LeciaSequist What are CTCs, ctDNA, exosomes and RNA? #LCSM
Dr. Amy C. Moore @acmoorephd
This is Amy Moore, Director of Science & Research for @GO2Foundation. Glad to be with y'all tonight and to learn more from two of my LC heroes, @CharuAggarwalMD and @LeciaSequist, about the power of liquid biopsies! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: T1. The most commonly used “#LiquidBiopsy” approach in clinical practice today relies on analysis of circulating tumor DNA, “shed” fragments of tumor DNA that can be extracted from blood, amplified and analyzed #LCSM
Lecia Sequist, MD, MPH @LeciaSequist
T1: An advantage for liq bx - they are less invasive/just a blood draw! However, you may not find material and a negative test does not prove "absence". As @dave6408 once said, not catching a fish doesn't mean the lake is empty. #LCSM https://t.co/skiLuQ96bP
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: T1: T1: In lung cancer, CTCs are especially prevalent in SCLC and have been used to make patient-derived models by @AnnaFaragoMD @LaurenByersMD and other groups too #LCSM https://t.co/8oPlb43fmQ https://t.co/gkDm8Nd1Bu
Mia Spano-Curtiss & Sondra Price @BSBreastCancer
#LCSM this is very good information and quite understandable ...
Christian Rolfo @ChristianRolfo
#lcsm
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: T1. Circulating tumor DNA (#ctDNA) is tumor-derived fragmented DNA in the bloodstream cell-free DNA (cfDNA) is a broader term which describes DNA that is freely circulating in the bloodstream, but is not necessarily of tumor origin #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@JFreemanDaily @LeciaSequist CTCs are circulating tumor cells, which are wandering tumor cells trying to find new homes. ctDNA is circulating Tumor DNA, which is most commonly used for plasma NGS assessment #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: T1: T1: Exosomes are tiny packets of intracellular material that pinch away from the cancer cell, surrounded by bubble-like membrane. They can contain bits of DNA, RNA, proteins, and may be one of the ways cells "talk" to each other #LCSM
Erika Hlavacek @ErikaHlavacek
RT @LeciaSequist: T1: T1: Exosomes are tiny packets of intracellular material that pinch away from the cancer cell, surrounded by bubble-like membrane. They can contain bits of DNA, RNA, proteins, and may be one of the ways cells "talk" to each other #LCSM
Ken @Flyers4Cup
RT @RedGia: Gia here from NC. Stage IV lung cancer since 9/2014. Looking forward to this discussion. #lcsm
Upstage Lung Cancer @UpstageLungCanc
RT @LeciaSequist: T1: T1: Exosomes are tiny packets of intracellular material that pinch away from the cancer cell, surrounded by bubble-like membrane. They can contain bits of DNA, RNA, proteins, and may be one of the ways cells "talk" to each other #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
T1. Evaluation of #ctDNA can be performed for single genes (e.g. #EGFR) alone or multi-panel testing-for many mutations at once. Single gene testing is often fast and cost-effective. Adding in a large panel can increase cost and turnaround time #LCSM
Mia Spano-Curtiss & Sondra Price @BSBreastCancer
#LCSM most commonly used #LiquidBiopsy read below
Geoff Oxnard, MD @geoff_oxnard
RT @lcsmchat: #LCSM Chat TODAY! Read more here: https://t.co/gyQSlR80sC… New to tweet chats? Read this primer: #LCSM Chat TODAY! Read more here: https://t.co/gyQSlR80sC… New to tweet chats? Read this primer: https://t.co/6MLl8di4X5 Join @JFreemanDaily @CharuAggarwalMD @LeciaSequist tonight at 8pm ET, 5pm PT for this *ALL* CANCERS CHAT! #hcsm https://t.co/qeK4pi4JlI
Dr. Amy C. Moore @acmoorephd
RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu
Upstage Lung Cancer @UpstageLungCanc
RT @CharuAggarwalMD: T1. Circulating tumor DNA (#ctDNA) is tumor-derived fragmented DNA in the bloodstream cell-free DNA (cfDNA) is a broader term which describes DNA that is freely circulating in the bloodstream, but is not necessarily of tumor origin #LCSM
#LCSM Chat @lcsmchat
@acmoorephd @GO2Foundation @CharuAggarwalMD @LeciaSequist Hi Amy! #lcsm
#LCSM Chat @lcsmchat
RT @LeciaSequist: T1: T1: An advantage for liq bx - they are less invasive/just a blood draw! However, you may not find material and a negative test does not prove "absence". As @dave6408 once said, not catching a fish doesn't mean the lake is empty. #LCSM https://t.co/skiLuQ96bP
Janet Freeman-Daily @JFreemanDaily
@BSBreastCancer You might want to retweet with #BCSM to share these tweets with your cancer community. The tweets already contain #LCSM.
Upstage Lung Cancer @UpstageLungCanc
RT @LeciaSequist: T1: T1: In lung cancer, CTCs are especially prevalent in SCLC and have been used to make patient-derived models by @AnnaFaragoMD @LaurenByersMD and other groups too #LCSM https://t.co/8oPlb43fmQ https://t.co/gkDm8Nd1Bu
Mia Spano-Curtiss & Sondra Price @BSBreastCancer
#LCSM
Dr. Amy C. Moore @acmoorephd
@lcsmchat @GO2Foundation @CharuAggarwalMD @LeciaSequist Good evening! #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
I love this graphic on a negative #LiquidBiopsy doesn't mean that it is truly negative #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @acmoorephd: This is Amy Moore, Director of Science & Research for @GO2Foundation. Glad to be with y'all tonight and to learn more from two of my LC heroes, @CharuAggarwalMD and @LeciaSequist, about the power of liquid biopsies! #lcsm
Upstage Lung Cancer @UpstageLungCanc
RT @CharuAggarwalMD: T1. The most commonly used “#LiquidBiopsy” approach in clinical practice today relies on analysis of circulating tumor DNA, “shed” fragments of tumor DNA that can be extracted from blood, amplified and analyzed #LCSM
#LCSM Chat @lcsmchat
RT @ChristianRolfo: #lcsm
Mia Spano-Curtiss & Sondra Price @BSBreastCancer
#LCSM
Upstage Lung Cancer @UpstageLungCanc
RT @LeciaSequist: T1: T1: Circulating tumor cells (CTCs) are rare, whole cells that break off from a cancer and can be captured by a variety of methods in the blood. While CTCs have not yet made it to clinical use, their potential as a modality for discovery re: cancer biology is large #LCSM
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: @JFreemanDaily @LeciaSequist CTCs are circulating tumor cells, which are wandering tumor cells trying to find new homes. ctDNA is circulating Tumor DNA, which is most commonly used for plasma NGS assessment #LCSM
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: T1. Evaluation of #ctDNA can be performed for single genes (e.g. #EGFR) alone or multi-panel testing-for many mutations at once. Single gene testing is often fast and cost-effective. Adding in a large panel can increase cost and turnaround time #LCSM
Jill Feldman @jillfeldman4
#LCSM
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: T1: T1: An advantage for liq bx - they are less invasive/just a blood draw! However, you may not find material and a negative test does not prove "absence". As @dave6408 once said, not catching a fish doesn't mean the lake is empty. #LCSM https://t.co/skiLuQ96bP
Upstage Lung Cancer @UpstageLungCanc
RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu
Mia Spano-Curtiss & Sondra Price @BSBreastCancer
#LCSM
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: I love this graphic on a negative #LiquidBiopsy doesn't mean that it is truly negative #LCSM
Jill Feldman @jillfeldman4
#LCSM
Mia Spano-Curtiss & Sondra Price @BSBreastCancer
#LCSM
Matthew Smeltzer @MattSmeltzer
RT @LeciaSequist: T1: T1: Circulating tumor cells (CTCs) are rare, whole cells that break off from a cancer and can be captured by a variety of methods in the blood. While CTCs have not yet made it to clinical use, their potential as a modality for discovery re: cancer biology is large #LCSM
Danielle Pardue @Actorielle
RT @CharuAggarwalMD: I love this graphic on a negative #LiquidBiopsy doesn't mean that it is truly negative #LCSM
Nirmal Raut @oncologician
@CharuAggarwalMD Is doing NGS from CTC better than cfDNA ? #LCSM
#LCSM Chat @lcsmchat
RT @oncologician: @CharuAggarwalMD Is doing NGS from CTC better than cfDNA ? #LCSM
Danielle Pardue @Actorielle
RT @CharuAggarwalMD: T1. Evaluation of #ctDNA can be performed for single genes (e.g. #EGFR) alone or multi-panel testing-for many mutations at once. Single gene testing is often fast and cost-effective. Adding in a large panel can increase cost and turnaround time #LCSM
Janet Freeman-Daily @JFreemanDaily
Love this analogy for liquid biopsies! "Not catching a fish doesn't mean the lake is empty." #lcsm
Danielle Pardue @Actorielle
RT @CharuAggarwalMD: @JFreemanDaily @LeciaSequist CTCs are circulating tumor cells, which are wandering tumor cells trying to find new homes. ctDNA is circulating Tumor DNA, which is most commonly used for plasma NGS assessment #LCSM
Danielle Pardue @Actorielle
RT @ChristianRolfo: #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @ChristianRolfo: #lcsm
Danielle Pardue @Actorielle
RT @CharuAggarwalMD: T1. Circulating tumor DNA (#ctDNA) is tumor-derived fragmented DNA in the bloodstream cell-free DNA (cfDNA) is a broader term which describes DNA that is freely circulating in the bloodstream, but is not necessarily of tumor origin #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: @JFreemanDaily @LeciaSequist CTCs are circulating tumor cells, which are wandering tumor cells trying to find new homes. ctDNA is circulating Tumor DNA, which is most commonly used for plasma NGS assessment #LCSM
Danielle Pardue @Actorielle
RT @LeciaSequist: T1: T1: In lung cancer, CTCs are especially prevalent in SCLC and have been used to make patient-derived models by @AnnaFaragoMD @LaurenByersMD and other groups too #LCSM https://t.co/8oPlb43fmQ https://t.co/gkDm8Nd1Bu
Lisa Briggs @livinglife82
Hello from Melbourne #Australia @lcsmchat looking forward to all things #liquidbiopsy #LCSM
Danielle Pardue @Actorielle
RT @CharuAggarwalMD: T1. The most commonly used “#LiquidBiopsy” approach in clinical practice today relies on analysis of circulating tumor DNA, “shed” fragments of tumor DNA that can be extracted from blood, amplified and analyzed #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: T1. Evaluation of #ctDNA can be performed for single genes (e.g. #EGFR) alone or multi-panel testing-for many mutations at once. Single gene testing is often fast and cost-effective. Adding in a large panel can increase cost and turnaround time #LCSM
Mia Spano-Curtiss & Sondra Price @BSBreastCancer
RT @lcsmchat: @BSBreastCancer @RedGia Welcome! So glad you’ve joined us. #lcsm
Danielle Pardue @Actorielle
RT @LeciaSequist: T1: T1: Circulating tumor cells (CTCs) are rare, whole cells that break off from a cancer and can be captured by a variety of methods in the blood. While CTCs have not yet made it to clinical use, their potential as a modality for discovery re: cancer biology is large #LCSM
Kristin Ito @KAdvocate_LCAM
T1. Similar to biomarker testing, with liquid biopsy do you have to be selective for what you are testing for? #LCSM #AlwaysLearning
Danielle Pardue @Actorielle
RT @LeciaSequist: T1: T1: @CharuAggarwalMD will tell you about ctDNA, which is in clinical use already. I'll tell you about some other types of liquid biopsies that aren't yet ready for prime time. also note there are hundreds of diff technological platforms, each with unique pro's and con's #LCSM
Danielle Pardue @Actorielle
RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu
Charu Aggarwal, MD, MPH @CharuAggarwalMD
T1. This graphic explains the different methods for gene sequencing, with single gene tests at the bottom having a very high degree of sensitivity and broad panel testing at the top, covering many genes, but can miss a positive mutation if present at low levels @NEJM #LCSM https://t.co/M5Xg9nz6wG
Christian Rolfo @ChristianRolfo
@JFreemanDaily @LeciaSequist Exosomes ( extra cellular vesicles) are a good tool to understand different biological process in cancer . Currently used as prognostic biomarkers (in research) for IO for example #lcsm @IsevOrg @islb @ddemiguelperez
#LCSM Chat @lcsmchat
@livinglife82 Hi Lisa! Belated Happy Birthday. #lcsm
Jill Feldman @jillfeldman4
Just because you don't catch a fish, it doesn't mean the lake is empty! #LCSM
Dr. Amy C. Moore @acmoorephd
It was a thrill and an honor to be part of this episode of @IASLC's "Lung Cancer Considered" podcast with two of the brightest minds in #lungcancer research, Drs. Paul Bunn and @StephenVLiu, and @moderna_tx's CMO, Dr. Tal Zaks! Listen to it March 8! #lcsm
Danielle Pardue @Actorielle
RT @CharuAggarwalMD: T1. This graphic explains the different methods for gene sequencing, with single gene tests at the bottom having a very high degree of sensitivity and broad panel testing at the top, covering many genes, but can miss a positive mutation if present at low levels @NEJM #LCSM https://t.co/M5Xg9nz6wG
Dr. Amy C. Moore @acmoorephd
@CharuAggarwalMD @lcsmchat @GO2Foundation @LeciaSequist Hi! #lcsm
Mia Spano-Curtiss & Sondra Price @BSBreastCancer
#LCSM #BCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
ctMONITR is an excellent example of how we need to pool resources to study the importance of serial ctDNA changes in #NSCLC #LCSM
Kristin Ito @KAdvocate_LCAM
@CharuAggarwalMD I think you answered my question in your recent post! #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
T1. I find that plasma #NGS testing of #ctDNA is timely (with turnaround time of 7-14 days), however can miss mutations in case of low overall tumor burden or low “shed” #LCSM
#LCSM Chat @lcsmchat
RT @KAdvocate_LCAM: T1. Similar to biomarker testing, with liquid biopsy do you have to be selective for what you are testing for? #LCSM #AlwaysLearning
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: T1. This graphic explains the different methods for gene sequencing, with single gene tests at the bottom having a very high degree of sensitivity and broad panel testing at the top, covering many genes, but can miss a positive mutation if present at low levels @NEJM #LCSM https://t.co/M5Xg9nz6wG
Mia Spano-Curtiss & Sondra Price @BSBreastCancer
#LCSM #BCSM
#LCSM Chat @lcsmchat
RT @ChristianRolfo: @JFreemanDaily @LeciaSequist Exosomes ( extra cellular vesicles) are a good tool to understand different biological process in cancer . Currently used as prognostic biomarkers (in research) for IO for example #lcsm @IsevOrg @islb @ddemiguelperez
Mia Spano-Curtiss & Sondra Price @BSBreastCancer
RT @acmoorephd: @CharuAggarwalMD @lcsmchat @GO2Foundation @LeciaSequist Hi! #lcsm
Lecia Sequist, MD, MPH @LeciaSequist
@KAdvocate_LCAM Yes, just like testing tumors you have to order the test that contains the info you are looking for and also be aware of what the test cannot do #LCSM
Janet Freeman-Daily @JFreemanDaily
@oncologician @CharuAggarwalMD In many cancers, cfDNA is more plentiful in the blood than CTC, so you have a better chance of an accurate test result with cfDNA in most cases. #LCSM
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: ctMONITR is an excellent example of how we need to pool resources to study the importance of serial ctDNA changes in #NSCLC #LCSM
Mia Spano-Curtiss & Sondra Price @BSBreastCancer
@acmoorephd @IASLC @StephenVLiu @moderna_tx #LCSM #BCSM
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: T1. I find that plasma #NGS testing of #ctDNA is timely (with turnaround time of 7-14 days), however can miss mutations in case of low overall tumor burden or low “shed” #LCSM
#LCSM Chat @lcsmchat
RT @LeciaSequist: @KAdvocate_LCAM Yes, just like testing tumors you have to order the test that contains the info you are looking for and also be aware of what the test cannot do #LCSM
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @oncologician @CharuAggarwalMD In many cancers, cfDNA is more plentiful in the blood than CTC, so you have a better chance of an accurate test result with cfDNA in most cases. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @KAdvocate_LCAM: T1. Similar to biomarker testing, with liquid biopsy do you have to be selective for what you are testing for? #LCSM #AlwaysLearning
Mia Spano-Curtiss & Sondra Price @BSBreastCancer
Happy Birthday Lisa from #BSBC
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: T1. This graphic explains the different methods for gene sequencing, with single gene tests at the bottom having a very high degree of sensitivity and broad panel testing at the top, covering many genes, but can miss a positive mutation if present at low levels @NEJM #LCSM https://t.co/M5Xg9nz6wG
Mia Spano-Curtiss & Sondra Price @BSBreastCancer
#LCSM #BCSM
Janet Freeman-Daily @JFreemanDaily
RT @ChristianRolfo: @JFreemanDaily @LeciaSequist Exosomes ( extra cellular vesicles) are a good tool to understand different biological process in cancer . Currently used as prognostic biomarkers (in research) for IO for example #lcsm @IsevOrg @islb @ddemiguelperez
Lecia Sequist, MD, MPH @LeciaSequist
@JFreemanDaily @oncologician @CharuAggarwalMD I agree with Janet. CTC assays are not reliable enough yet, or widely available enough to do clinical genotyping for selection of targeted therapy. This is ctDNA's strongest niche! #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: ctMONITR is an excellent example of how we need to pool resources to study the importance of serial ctDNA changes in #NSCLC #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
T2. We and others @PennMedicine have demonstrated that serial monitoring of #ctDNA can be used as a biomarker of response to immunotherapy, with patients having a drop in ctDNA following immunotherapy following immunotherapy #LCSM @ASCO https://t.co/v6WyeOMorT https://t.co/PBiw750195
Lecia Sequist, MD, MPH @LeciaSequist
T2: Liquid bx (ctDNA) is commonly used in lung cancer clinics today to identify actionable mutations in advanced adeno and can be additive to tissue NGS. Here's a great example from @CharuAggarwalMD @Jbauml @CoreyLangerMD https://t.co/5UJmen6MlD #LCSM https://t.co/PB3O17BNzl
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: T1. I find that plasma #NGS testing of #ctDNA is timely (with turnaround time of 7-14 days), however can miss mutations in case of low overall tumor burden or low “shed” #LCSM
Danielle Pardue @Actorielle
RT @LeciaSequist: @JFreemanDaily @oncologician @CharuAggarwalMD I agree with Janet. CTC assays are not reliable enough yet, or widely available enough to do clinical genotyping for selection of targeted therapy. This is ctDNA's strongest niche! #LCSM
Janet Freeman-Daily @JFreemanDaily
T2. How might liquid Bx be used for treatment monitoring and detecting disease progression? #lcsm
#LCSM Chat @lcsmchat
RT @LeciaSequist: @JFreemanDaily @oncologician @CharuAggarwalMD I agree with Janet. CTC assays are not reliable enough yet, or widely available enough to do clinical genotyping for selection of targeted therapy. This is ctDNA's strongest niche! #LCSM
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: T2. We and others @PennMedicine have demonstrated that serial monitoring of #ctDNA can be used as a biomarker of response to immunotherapy, with patients having a drop in ctDNA following immunotherapy following immunotherapy #LCSM @ASCO https://t.co/v6WyeOMorT https://t.co/PBiw750195
Jill Feldman @jillfeldman4
RT @CharuAggarwalMD: T2. We and others @PennMedicine have demonstrated that serial monitoring of #ctDNA can be used as a biomarker of response to immunotherapy, with patients having a drop in ctDNA following immunotherapy following immunotherapy #LCSM @ASCO https://t.co/v6WyeOMorT https://t.co/PBiw750195
Danielle Pardue @Actorielle
RT @LeciaSequist: T2: T2: Liquid bx (ctDNA) is commonly used in lung cancer clinics today to identify actionable mutations in advanced adeno and can be additive to tissue NGS. Here's a great example from @CharuAggarwalMD @Jbauml @CoreyLangerMD https://t.co/5UJmen6MlD #LCSM https://t.co/PB3O17BNzl
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: @KAdvocate_LCAM Yes, just like testing tumors you have to order the test that contains the info you are looking for and also be aware of what the test cannot do #LCSM
#LCSM Chat @lcsmchat
RT @LeciaSequist: T2: T2: Liquid bx (ctDNA) is commonly used in lung cancer clinics today to identify actionable mutations in advanced adeno and can be additive to tissue NGS. Here's a great example from @CharuAggarwalMD @Jbauml @CoreyLangerMD https://t.co/5UJmen6MlD #LCSM https://t.co/PB3O17BNzl
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T2. How might liquid Bx be used for treatment monitoring and detecting disease progression? #lcsm
Lecia Sequist, MD, MPH @LeciaSequist
T2: Clearance of ctDNA with targeted therapy has consistently been shown to be a good prognostic factor. Here's one example from FLAURA by Jhanelle Gray @RamalingamMD #LCSM https://t.co/L34gUpjgbk
Upstage Lung Cancer @UpstageLungCanc
RT @LeciaSequist: T2: T2: Liquid bx (ctDNA) is commonly used in lung cancer clinics today to identify actionable mutations in advanced adeno and can be additive to tissue NGS. Here's a great example from @CharuAggarwalMD @Jbauml @CoreyLangerMD https://t.co/5UJmen6MlD #LCSM https://t.co/PB3O17BNzl
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: @JFreemanDaily @oncologician @CharuAggarwalMD I agree with Janet. CTC assays are not reliable enough yet, or widely available enough to do clinical genotyping for selection of targeted therapy. This is ctDNA's strongest niche! #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: T2. We and others @PennMedicine have demonstrated that serial monitoring of #ctDNA can be used as a biomarker of response to immunotherapy, with patients having a drop in ctDNA following immunotherapy following immunotherapy #LCSM @ASCO https://t.co/v6WyeOMorT https://t.co/PBiw750195
Charu Aggarwal, MD, MPH @CharuAggarwalMD
RT @LeciaSequist: T2: T2: Clearance of ctDNA with targeted therapy has consistently been shown to be a good prognostic factor. Here's one example from FLAURA by Jhanelle Gray @RamalingamMD #LCSM https://t.co/L34gUpjgbk
#LCSM Chat @lcsmchat
RT @LeciaSequist: T2: T2: Clearance of ctDNA with targeted therapy has consistently been shown to be a good prognostic factor. Here's one example from FLAURA by Jhanelle Gray @RamalingamMD #LCSM https://t.co/L34gUpjgbk
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: T2: T2: Liquid bx (ctDNA) is commonly used in lung cancer clinics today to identify actionable mutations in advanced adeno and can be additive to tissue NGS. Here's a great example from @CharuAggarwalMD @Jbauml @CoreyLangerMD https://t.co/5UJmen6MlD #LCSM https://t.co/PB3O17BNzl
Charu Aggarwal, MD, MPH @CharuAggarwalMD
RT @LeciaSequist: T2: T2: Liquid bx (ctDNA) is commonly used in lung cancer clinics today to identify actionable mutations in advanced adeno and can be additive to tissue NGS. Here's a great example from @CharuAggarwalMD @Jbauml @CoreyLangerMD https://t.co/5UJmen6MlD #LCSM https://t.co/PB3O17BNzl
Kristin Ito @KAdvocate_LCAM
RT @JFreemanDaily: T2. How might liquid Bx be used for treatment monitoring and detecting disease progression? #lcsm
kristen kimball @KimballKristen
RT @LeciaSequist: T2: T2: Liquid bx (ctDNA) is commonly used in lung cancer clinics today to identify actionable mutations in advanced adeno and can be additive to tissue NGS. Here's a great example from @CharuAggarwalMD @Jbauml @CoreyLangerMD https://t.co/5UJmen6MlD #LCSM https://t.co/PB3O17BNzl
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: T2: T2: Clearance of ctDNA with targeted therapy has consistently been shown to be a good prognostic factor. Here's one example from FLAURA by Jhanelle Gray @RamalingamMD #LCSM https://t.co/L34gUpjgbk
Jill Feldman @jillfeldman4
RT @LeciaSequist: T2: T2: Clearance of ctDNA with targeted therapy has consistently been shown to be a good prognostic factor. Here's one example from FLAURA by Jhanelle Gray @RamalingamMD #LCSM https://t.co/L34gUpjgbk
Dave Bjork @bjork5
#LCSM
Upstage Lung Cancer @UpstageLungCanc
RT @LeciaSequist: T2: T2: Clearance of ctDNA with targeted therapy has consistently been shown to be a good prognostic factor. Here's one example from FLAURA by Jhanelle Gray @RamalingamMD #LCSM https://t.co/L34gUpjgbk
Danielle Pardue @Actorielle
RT @LeciaSequist: T2: T2: Clearance of ctDNA with targeted therapy has consistently been shown to be a good prognostic factor. Here's one example from FLAURA by Jhanelle Gray @RamalingamMD #LCSM https://t.co/L34gUpjgbk
Mia Spano-Curtiss & Sondra Price @BSBreastCancer
#LCSM #BCSM
Mia Spano-Curtiss & Sondra Price @BSBreastCancer
RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu
Jill Feldman @jillfeldman4
#LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
T2. These are not quite ready for #primetime just yet although emerging evidence suggests that we could successfully integrate these findings into clinical practice in the future #LCSM https://t.co/tOABZ4CmiM https://t.co/QjJlZfI14s
Lecia Sequist, MD, MPH @LeciaSequist
T2: ctDNA can also be used to follow response and resistance to targeted therapy and show various clones and resistance mech's. There are myriad examples of this, here's one by @ZPiotrowskaMD #JCOOP #LCSM https://t.co/r8Gdu1WcHe
Kristin Ito @KAdvocate_LCAM
T2. If this is beneficial, are there major cost barriers to be considerate of? Insurance is a beast. #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
RT @LeciaSequist: T2: T2: ctDNA can also be used to follow response and resistance to targeted therapy and show various clones and resistance mech's. There are myriad examples of this, here's one by @ZPiotrowskaMD #JCOOP #LCSM https://t.co/r8Gdu1WcHe
Eric Bernicker @EricBernicker
Most platforms will test for a panel of common mutations. ( Fortunately for most oncologists you don't need to specify every mutation you are looking for 0 #LCSM
Danielle Pardue @Actorielle
RT @CharuAggarwalMD: T2. These are not quite ready for #primetime just yet although emerging evidence suggests that we could successfully integrate these findings into clinical practice in the future #LCSM https://t.co/tOABZ4CmiM https://t.co/QjJlZfI14s
Danielle Pardue @Actorielle
RT @LeciaSequist: T2: T2: ctDNA can also be used to follow response and resistance to targeted therapy and show various clones and resistance mech's. There are myriad examples of this, here's one by @ZPiotrowskaMD #JCOOP #LCSM https://t.co/r8Gdu1WcHe
Janet Freeman-Daily @JFreemanDaily
@LeciaSequist @RamalingamMD So if you don't see ctDNA after #cancer treatment, it's a good chance the treatment worked well? #LCSM
Lisa Briggs @livinglife82
T1: From a #patient perspective Pros - minimally invasive, easy to perform, more pleasant experience than trad. biopsy Cons - Treatments are NOT subsidized in 🇦🇺 following a #liquidbiopsy, if progression is in the brain high levels of ctDNA are required to obtain info #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
T2. Another biomarker that can be assessed using plasma ctDNA is #TMB #LCSM
Lecia Sequist, MD, MPH @LeciaSequist
T2: One thing we aren't sure of yet is when/if/how to react to a resistance mechanism found on ctDNA in the absence of radiographic or symptomatic progression. Prospective trials are needed! #LCSM
Nathan A. Pennell MD, PhD, FASCO @n8pennell
RT @CharuAggarwalMD: T2. These are not quite ready for #primetime just yet although emerging evidence suggests that we could successfully integrate these findings into clinical practice in the future #LCSM https://t.co/tOABZ4CmiM https://t.co/QjJlZfI14s
Upstage Lung Cancer @UpstageLungCanc
RT @LeciaSequist: T2: T2: ctDNA can also be used to follow response and resistance to targeted therapy and show various clones and resistance mech's. There are myriad examples of this, here's one by @ZPiotrowskaMD #JCOOP #LCSM https://t.co/r8Gdu1WcHe
Dr. Amy C. Moore @acmoorephd
@LeciaSequist @lcsmchat @JFreemanDaily @oncologician @CharuAggarwalMD I got asked about use of liquid Bx for #SCLC the other day. Do CTCs come more into play in this setting? #lcsm
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: T2. These are not quite ready for #primetime just yet although emerging evidence suggests that we could successfully integrate these findings into clinical practice in the future #LCSM https://t.co/tOABZ4CmiM https://t.co/QjJlZfI14s
Jill Feldman @jillfeldman4
#LCSM
#LCSM Chat @lcsmchat
RT @LeciaSequist: T2: T2: ctDNA can also be used to follow response and resistance to targeted therapy and show various clones and resistance mech's. There are myriad examples of this, here's one by @ZPiotrowskaMD #JCOOP #LCSM https://t.co/r8Gdu1WcHe
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: T2. These are not quite ready for #primetime just yet although emerging evidence suggests that we could successfully integrate these findings into clinical practice in the future #LCSM https://t.co/tOABZ4CmiM https://t.co/QjJlZfI14s
Upstage Lung Cancer @UpstageLungCanc
RT @CharuAggarwalMD: T2. These are not quite ready for #primetime just yet although emerging evidence suggests that we could successfully integrate these findings into clinical practice in the future #LCSM https://t.co/tOABZ4CmiM https://t.co/QjJlZfI14s
#LCSM Chat @lcsmchat
RT @KAdvocate_LCAM: T2. If this is beneficial, are there major cost barriers to be considerate of? Insurance is a beast. #LCSM
#LCSM Chat @lcsmchat
RT @EricBernicker: Most platforms will test for a panel of common mutations. ( Fortunately for most oncologists you don't need to specify every mutation you are looking for 0 #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: T2: T2: ctDNA can also be used to follow response and resistance to targeted therapy and show various clones and resistance mech's. There are myriad examples of this, here's one by @ZPiotrowskaMD #JCOOP #LCSM https://t.co/r8Gdu1WcHe
Erika Hlavacek @ErikaHlavacek
RT @CharuAggarwalMD: T2. These are not quite ready for #primetime just yet although emerging evidence suggests that we could successfully integrate these findings into clinical practice in the future #LCSM https://t.co/tOABZ4CmiM https://t.co/QjJlZfI14s
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @LeciaSequist @RamalingamMD So if you don't see ctDNA after #cancer treatment, it's a good chance the treatment worked well? #LCSM
Sanjay Mukhopadhyay @smlungpathguy
Tweet of the day 👇🏾🔥 This is the best line ever to use when a “proceduralist” asks you how it can be that their biopsy doesn’t have diagnostic material. “NOT CATCHING A FISH DOESN’T MEAN THE LAKE IS EMPTY”
#LCSM Chat @lcsmchat
RT @livinglife82: T1: T1: From a #patient perspective Pros - minimally invasive, easy to perform, more pleasant experience than trad. biopsy Cons - Treatments are NOT subsidized in 🇦🇺 following a #liquidbiopsy, if progression is in the brain high levels of ctDNA are required to obtain info #LCSM
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: T2. Another biomarker that can be assessed using plasma ctDNA is #TMB #LCSM
#LCSM Chat @lcsmchat
RT @LeciaSequist: T2: T2: One thing we aren't sure of yet is when/if/how to react to a resistance mechanism found on ctDNA in the absence of radiographic or symptomatic progression. Prospective trials are needed! #LCSM
#LCSM Chat @lcsmchat
RT @acmoorephd: @LeciaSequist @lcsmchat @JFreemanDaily @oncologician @CharuAggarwalMD I got asked about use of liquid Bx for #SCLC the other day. Do CTCs come more into play in this setting? #lcsm
Lisa Briggs @livinglife82
RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu
Charu Aggarwal, MD, MPH @CharuAggarwalMD
T2. Tumor gene mutation burden (TMB) is the approx amount of gene mutations that occur in the a cancer cell. Usually measured using whole genome sequencing, we can get it with plasma #NGS panels @drgandara @VamsiVelcheti https://t.co/VPTrvHKVWW https://t.co/PIxa6K8CGD #LCSM
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: T2. Tumor gene mutation burden (TMB) is the approx amount of gene mutations that occur in the a cancer cell. Usually measured using whole genome sequencing, we can get it with plasma #NGS panels @drgandara @VamsiVelcheti https://t.co/VPTrvHKVWW https://t.co/PIxa6K8CGD #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@JFreemanDaily @LeciaSequist @RamalingamMD Likely. Clinical trials are now ongoing to escalate therapy for those with persistent ctDNA. I think this will be a valuable resource in the future #LCSM
Christian Rolfo @ChristianRolfo
@LeciaSequist @RamalingamMD This is an important concept we see using in monitoring. In addition of the dynamic of VAF, agood prognostic biomarker in immuno and targeted therapies. #lcsm @isliquidbiopsy
Michael Kelley, MD @kelleymic
#VACancerCare @VeteransHealth @DeptVetAffairs @VAResearch
Janet Freeman-Daily @JFreemanDaily
@KAdvocate_LCAM The applications of #liquidbiopsy that @CharuAggarwalMD and @LeciaSequist are discussion in the chat are still in development. So far, only liquid bx test approved is to identify specific genomic drivers (biomarkers) in #lungcancer. #LCSM
Lisa Briggs @livinglife82
RT @CharuAggarwalMD: T1. This graphic explains the different methods for gene sequencing, with single gene tests at the bottom having a very high degree of sensitivity and broad panel testing at the top, covering many genes, but can miss a positive mutation if present at low levels @NEJM #LCSM https://t.co/M5Xg9nz6wG
Janet Freeman-Daily @JFreemanDaily
RT @KAdvocate_LCAM: T2. If this is beneficial, are there major cost barriers to be considerate of? Insurance is a beast. #LCSM
Jill Feldman @jillfeldman4
This is definitely an unmet need. It is anxiety-provoking for patients, and I'm sure oncs as well. #LCSM
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: @JFreemanDaily @LeciaSequist @RamalingamMD Likely. Clinical trials are now ongoing to escalate therapy for those with persistent ctDNA. I think this will be a valuable resource in the future #LCSM
#LCSM Chat @lcsmchat
RT @ChristianRolfo: @LeciaSequist @RamalingamMD This is an important concept we see using in monitoring. In addition of the dynamic of VAF, agood prognostic biomarker in immuno and targeted therapies. #lcsm @isliquidbiopsy
Liz Szabo @LizSzabo
RT @BSBreastCancer: Who's joining in for the #LCSM Chat tonight? All Cancers Chat #bcsm #btsm #ayacsm #gyncsm #orosm #Pcsm @LizSzabo
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @KAdvocate_LCAM The applications of #liquidbiopsy that @CharuAggarwalMD and @LeciaSequist are discussion in the chat are still in development. So far, only liquid bx test approved is to identify specific genomic drivers (biomarkers) in #lungcancer. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @EricBernicker: Most platforms will test for a panel of common mutations. ( Fortunately for most oncologists you don't need to specify every mutation you are looking for 0 #LCSM
#LCSM Chat @lcsmchat
RT @jillfeldman4: This is definitely an unmet need. It is anxiety-provoking for patients, and I'm sure oncs as well. #LCSM
Nathan A. Pennell MD, PhD, FASCO @n8pennell
@CharuAggarwalMD @JFreemanDaily @LeciaSequist @RamalingamMD Yes the ability to intervene in high risk patients is key, otherwise it’s not that helpful to know a worse prognosis! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: @JFreemanDaily @LeciaSequist @RamalingamMD Likely. Clinical trials are now ongoing to escalate therapy for those with persistent ctDNA. I think this will be a valuable resource in the future #LCSM
Erika Hlavacek @ErikaHlavacek
#lcsm
Janet Freeman-Daily @JFreemanDaily
RT @n8pennell: @CharuAggarwalMD @JFreemanDaily @LeciaSequist @RamalingamMD Yes the ability to intervene in high risk patients is key, otherwise it’s not that helpful to know a worse prognosis! #lcsm
Eric Bernicker @EricBernicker
Financial toxicity is always a concern but most test are covered, certainly at diagnosis. But the real financial toxicity would be missing an actionable mutation and getting expensive and possibly ineffective immunotherapy ...#LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@acmoorephd @LeciaSequist @lcsmchat @JFreemanDaily @oncologician CTCs are more plentiful in SCLC than SCLC, and we have had some experience with genotyping SCLC CTCs successfully. Again, more research based at this time #LCSM
#LCSM Chat @lcsmchat
#lcsm
Janet Freeman-Daily @JFreemanDaily
RT @livinglife82: T1: T1: From a #patient perspective Pros - minimally invasive, easy to perform, more pleasant experience than trad. biopsy Cons - Treatments are NOT subsidized in 🇦🇺 following a #liquidbiopsy, if progression is in the brain high levels of ctDNA are required to obtain info #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: T2. Another biomarker that can be assessed using plasma ctDNA is #TMB #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: T2: T2: One thing we aren't sure of yet is when/if/how to react to a resistance mechanism found on ctDNA in the absence of radiographic or symptomatic progression. Prospective trials are needed! #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @acmoorephd: @LeciaSequist @lcsmchat @JFreemanDaily @oncologician @CharuAggarwalMD I got asked about use of liquid Bx for #SCLC the other day. Do CTCs come more into play in this setting? #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: T2. Tumor gene mutation burden (TMB) is the approx amount of gene mutations that occur in the a cancer cell. Usually measured using whole genome sequencing, we can get it with plasma #NGS panels @drgandara @VamsiVelcheti https://t.co/VPTrvHKVWW https://t.co/PIxa6K8CGD #LCSM
#LCSM Chat @lcsmchat
RT @n8pennell: @CharuAggarwalMD @JFreemanDaily @LeciaSequist @RamalingamMD Yes the ability to intervene in high risk patients is key, otherwise it’s not that helpful to know a worse prognosis! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @ChristianRolfo: @LeciaSequist @RamalingamMD This is an important concept we see using in monitoring. In addition of the dynamic of VAF, agood prognostic biomarker in immuno and targeted therapies. #lcsm @isliquidbiopsy
#LCSM Chat @lcsmchat
RT @EricBernicker: Financial toxicity is always a concern but most test are covered, certainly at diagnosis. But the real financial toxicity would be missing an actionable mutation and getting expensive and possibly ineffective immunotherapy ...#LCSM
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: @acmoorephd @LeciaSequist @lcsmchat @JFreemanDaily @oncologician CTCs are more plentiful in SCLC than SCLC, and we have had some experience with genotyping SCLC CTCs successfully. Again, more research based at this time #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @jillfeldman4: This is definitely an unmet need. It is anxiety-provoking for patients, and I'm sure oncs as well. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @EricBernicker: Financial toxicity is always a concern but most test are covered, certainly at diagnosis. But the real financial toxicity would be missing an actionable mutation and getting expensive and possibly ineffective immunotherapy ...#LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
RT @EricBernicker: Financial toxicity is always a concern but most test are covered, certainly at diagnosis. But the real financial toxicity would be missing an actionable mutation and getting expensive and possibly ineffective immunotherapy ...#LCSM
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: @acmoorephd @LeciaSequist @lcsmchat @JFreemanDaily @oncologician CTCs are more plentiful in SCLC than SCLC, and we have had some experience with genotyping SCLC CTCs successfully. Again, more research based at this time #LCSM
Christina Lizaso @btrfly12
RT @jillfeldman4: Just because you don't catch a fish, it doesn't mean the lake is empty! #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @lcsmchat: #lcsm
MaryAnn Bradley @Dollybrad
RT @Kamacintosh: TY @DoctorJSpicer for supporting our movement as it spreads across North America! @TWRP Canada is Coast to Coast. We appreciate your support to #LungCancer community in Raising #Awareness 4 #1 #Cancer Killer #TheWhiteRibbonProject #LCSM #AllYouNeedIsLungs #AnyoneCanGetLungCancer https://t.co/vcMYvAym1z
Lecia Sequist, MD, MPH @LeciaSequist
@JFreemanDaily @RamalingamMD This assumption is predicated on the fact that there WAS detectable ctDNA w/ the same assay before therapy. If not detectable pre-rx, can't follow conversion to undetectable as a potential biomarker #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: @JFreemanDaily @RamalingamMD This assumption is predicated on the fact that there WAS detectable ctDNA w/ the same assay before therapy. If not detectable pre-rx, can't follow conversion to undetectable as a potential biomarker #LCSM
#LCSM Chat @lcsmchat
RT @LeciaSequist: @JFreemanDaily @RamalingamMD This assumption is predicated on the fact that there WAS detectable ctDNA w/ the same assay before therapy. If not detectable pre-rx, can't follow conversion to undetectable as a potential biomarker #LCSM
Christina Lizaso @btrfly12
RT @LeciaSequist: T1: T1: There are multiple "analytes" in the blood, any of which could be assayed via a "liquid biopsy". I like this graphic from Jia et al, Oncotarget 2017 showing how blood contains CTCs, ctDNA, exosomes and RNA (and I would add proteins) in addition to blood cells #LCSM https://t.co/58M9UStyfu
Christian Rolfo @ChristianRolfo
#lcsm
Janet Freeman-Daily @JFreemanDaily
#LCSM
Lisa Briggs @livinglife82
T2 - Is the sensitivity of detecting disease progression through #liquidbiopsy highly dependent on the region progression has occurred. Eg more likely to detect it if it’s in the lung vs brain or bone. OR is it largely based on the turnover of cells shedding? #LCSM
Lecia Sequist, MD, MPH @LeciaSequist
T3: One of the clearest examples of ctDNA being used to assess MRD is by @max_diehn and team, who showed that detectable ctDNA after radiation for early stage NSCLC is a poor prognostic factor #LCSM https://t.co/1xhYDih97r
Janet Freeman-Daily @JFreemanDaily
T3. How might liquid Bx be used for prognosis or to measure cancer remaining after treatment? #lcsm
Triage Cancer @TriageCancer
@JFreemanDaily @KAdvocate_LCAM @CharuAggarwalMD @LeciaSequist There are free resources about navigating health insurance, health insurance appeals, and other issues related to payment for various biomarker tests at our website: https://t.co/zY7CesHqJn and also https://t.co/5IxhJu4Y0S #lcsm
#LCSM Chat @lcsmchat
RT @ChristianRolfo: #lcsm
Christina Lizaso @btrfly12
RT @JFreemanDaily: Welcome to #LCSM Chat! Tonight’s chat will discuss “Liquid Bx—It pays to be vein.” (Bx=biopsy) More info on our blog at https://t.co/0hz3jRwX1g
#LCSM Chat @lcsmchat
RT @livinglife82: T2 - Is the sensitivity of detecting disease progression through #liquidbiopsy highly dependent on the region progression has occurred. Eg more likely to detect it if it’s in the lung vs brain or bone. OR is it largely based on the turnover of cells shedding? #LCSM
#LCSM Chat @lcsmchat
RT @LeciaSequist: T3: T3: One of the clearest examples of ctDNA being used to assess MRD is by @max_diehn and team, who showed that detectable ctDNA after radiation for early stage NSCLC is a poor prognostic factor #LCSM https://t.co/1xhYDih97r
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T3. How might liquid Bx be used for prognosis or to measure cancer remaining after treatment? #lcsm
Christina Lizaso @btrfly12
RT @JFreemanDaily: T3. How might liquid Bx be used for prognosis or to measure cancer remaining after treatment? #lcsm
#LCSM Chat @lcsmchat
RT @TriageCancer: @JFreemanDaily @KAdvocate_LCAM @CharuAggarwalMD @LeciaSequist There are free resources about navigating health insurance, health insurance appeals, and other issues related to payment for various biomarker tests at our website: https://t.co/zY7CesHqJn and also https://t.co/5IxhJu4Y0S #lcsm
Dr. Amy C. Moore @acmoorephd
RT @CharuAggarwalMD: @acmoorephd @LeciaSequist @lcsmchat @JFreemanDaily @oncologician CTCs are more plentiful in SCLC than SCLC, and we have had some experience with genotyping SCLC CTCs successfully. Again, more research based at this time #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @ErikaHlavacek: #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
T3. The concept of “minimal residual disease” has been traditionally used in leukemia. Relies on the detection of remaining ctDNA to detect high risk individuals that may still have circulating disease burden that can be targeted for additional therapy! @max_diehn #LCSM
Lecia Sequist, MD, MPH @LeciaSequist
T3: A key point is that we need to conduct prospective clinical trials before using MRD markers to guide therapy. We need to prove that such guided strategies improve outcomes #LCSM
Christina Lizaso @btrfly12
RT @JFreemanDaily: @KAdvocate_LCAM The applications of #liquidbiopsy that @CharuAggarwalMD and @LeciaSequist are discussion in the chat are still in development. So far, only liquid bx test approved is to identify specific genomic drivers (biomarkers) in #lungcancer. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @livinglife82: T2 - Is the sensitivity of detecting disease progression through #liquidbiopsy highly dependent on the region progression has occurred. Eg more likely to detect it if it’s in the lung vs brain or bone. OR is it largely based on the turnover of cells shedding? #LCSM
#LCSM Chat @lcsmchat
RT @LeciaSequist: T3: T3: A key point is that we need to conduct prospective clinical trials before using MRD markers to guide therapy. We need to prove that such guided strategies improve outcomes #LCSM
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: T3. The concept of “minimal residual disease” has been traditionally used in leukemia. Relies on the detection of remaining ctDNA to detect high risk individuals that may still have circulating disease burden that can be targeted for additional therapy! @max_diehn #LCSM
Christina Lizaso @btrfly12
RT @CharuAggarwalMD: T2. Tumor gene mutation burden (TMB) is the approx amount of gene mutations that occur in the a cancer cell. Usually measured using whole genome sequencing, we can get it with plasma #NGS panels @drgandara @VamsiVelcheti https://t.co/VPTrvHKVWW https://t.co/PIxa6K8CGD #LCSM
Coach Duff @CoachDuff
RT @bjork5: Hi friends, Dave Bjork here in Boston, host of the https://t.co/WePGnEdkmc #LCSM
Lecia Sequist, MD, MPH @LeciaSequist
@livinglife82 Great question and both have shown to correlate w/ more ctDNA. It's a combo of biology of tumor, location/ amount of mets, and sensitivity of the assay. A positive test is informative, but a negative test is not that useful. (see fish picture again !) #LCSM https://t.co/zf258X44Am
Janet Freeman-Daily @JFreemanDaily
@livinglife82 My understanding: at present, #liquidbiopsy is not effective at detecting cancer or other biomarkers in the brain. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: T3: T3: One of the clearest examples of ctDNA being used to assess MRD is by @max_diehn and team, who showed that detectable ctDNA after radiation for early stage NSCLC is a poor prognostic factor #LCSM https://t.co/1xhYDih97r
Kristin Ito @KAdvocate_LCAM
RT @LeciaSequist: T3: T3: A key point is that we need to conduct prospective clinical trials before using MRD markers to guide therapy. We need to prove that such guided strategies improve outcomes #LCSM
#LCSM Chat @lcsmchat
RT @LeciaSequist: @livinglife82 Great question and both have shown to correlate w/ more ctDNA. It's a combo of biology of tumor, location/ amount of mets, and sensitivity of the assay. A positive test is informative, but a negative test is not that useful. (see fish picture again !) #LCSM https://t.co/zf258X44Am
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: T3: T3: A key point is that we need to conduct prospective clinical trials before using MRD markers to guide therapy. We need to prove that such guided strategies improve outcomes #LCSM
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @livinglife82 My understanding: @livinglife82 My understanding: at present, #liquidbiopsy is not effective at detecting cancer or other biomarkers in the brain. #LCSM
Christian Rolfo @ChristianRolfo
@JFreemanDaily #lcsm MRD is a great scenario for research and her we can recuperate CTCs as a tool to detect disease after surgery like in this trial https://t.co/KozoaWb8Hn
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: T3. The concept of “minimal residual disease” has been traditionally used in leukemia. Relies on the detection of remaining ctDNA to detect high risk individuals that may still have circulating disease burden that can be targeted for additional therapy! @max_diehn #LCSM
Nathan A. Pennell MD, PhD, FASCO @n8pennell
@LeciaSequist @max_diehn I think this will be the future of monitoring for recurrence after potentially curative treatment for cancer! again though ability to intervene when still positive is key #lcsm
Nathan A. Pennell MD, PhD, FASCO @n8pennell
RT @LeciaSequist: T3: T3: One of the clearest examples of ctDNA being used to assess MRD is by @max_diehn and team, who showed that detectable ctDNA after radiation for early stage NSCLC is a poor prognostic factor #LCSM https://t.co/1xhYDih97r
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: @livinglife82 Great question and both have shown to correlate w/ more ctDNA. It's a combo of biology of tumor, location/ amount of mets, and sensitivity of the assay. A positive test is informative, but a negative test is not that useful. (see fish picture again !) #LCSM https://t.co/zf258X44Am
#LCSM Chat @lcsmchat
RT @ChristianRolfo: @JFreemanDaily #lcsm MRD is a great scenario for research and her we can recuperate CTCs as a tool to detect disease after surgery like in this trial https://t.co/KozoaWb8Hn
Charu Aggarwal, MD, MPH @CharuAggarwalMD
T3. We could apply the concept of “minimal residual disease” to the setting of Early Stage #LungCancer and Locally Advanced #LungCancer to identify individuals with #ctDNA, who can be selected for additional therapy #LCSM https://t.co/kBTdPDGJJh
Janet Freeman-Daily @JFreemanDaily
RT @ChristianRolfo: @JFreemanDaily #lcsm MRD is a great scenario for research and her we can recuperate CTCs as a tool to detect disease after surgery like in this trial https://t.co/KozoaWb8Hn
Mia Spano-Curtiss & Sondra Price @BSBreastCancer
#LCSM #BCSM
#LCSM Chat @lcsmchat
RT @n8pennell: @LeciaSequist @max_diehn I think this will be the future of monitoring for recurrence after potentially curative treatment for cancer! again though ability to intervene when still positive is key #lcsm
Janet Freeman-Daily @JFreemanDaily
@ChristianRolfo @ChristianRolfo Thanks for all your great tweets in tonight's #LCSM Chat!
Lecia Sequist, MD, MPH @LeciaSequist
@oncologician @acmoorephd @lcsmchat @JFreemanDaily @CharuAggarwalMD @LaurenByersMD @triparnasen @christine_lovly @cbmeador Depends on the method that you are using to collect CTCs. Some methods are "rough" and break apart the CTCs, spilling contents. Others are "gentle" and keep cells whole. Also WBCs contaminating CTCs can raise the "noise" compared to "signal" and contribute CH findings #LCSM
Nathan A. Pennell MD, PhD, FASCO @n8pennell
@LeciaSequist Have this planned in EA 5181 chemo radiation trial for stage 3 NSCLC and others too I’m sure! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @n8pennell: @LeciaSequist @max_diehn I think this will be the future of monitoring for recurrence after potentially curative treatment for cancer! again though ability to intervene when still positive is key #lcsm
Aliye Bricker @AliyeBricker
@LeciaSequist @lcsmchat If a liquid biopsy does not show the presence of a new resistance mechanism (such as a gate keeper mutation or solvent front mutation) despite clear evidence of progression on imaging, is it worth pursuing a tissue biopsy from a site of disease progression? #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: T3. We could apply the concept of “minimal residual disease” to the setting of Early Stage #LungCancer and Locally Advanced #LungCancer to identify individuals with #ctDNA, who can be selected for additional therapy #LCSM https://t.co/kBTdPDGJJh
Lisa Briggs @livinglife82
RT @LeciaSequist: @livinglife82 Great question and both have shown to correlate w/ more ctDNA. It's a combo of biology of tumor, location/ amount of mets, and sensitivity of the assay. A positive test is informative, but a negative test is not that useful. (see fish picture again !) #LCSM https://t.co/zf258X44Am
Nirmal Raut @oncologician
RT @LeciaSequist: @oncologician @acmoorephd @lcsmchat @JFreemanDaily @CharuAggarwalMD @LaurenByersMD @triparnasen @christine_lovly @cbmeador Depends on the method that you are using to collect CTCs. Some methods are "rough" and break apart the CTCs, spilling contents. Others are "gentle" and keep cells whole. Also WBCs contaminating CTCs can raise the "noise" compared to "signal" and contribute CH findings #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: @oncologician @acmoorephd @lcsmchat @JFreemanDaily @CharuAggarwalMD @LaurenByersMD @triparnasen @christine_lovly @cbmeador Depends on the method that you are using to collect CTCs. Some methods are "rough" and break apart the CTCs, spilling contents. Others are "gentle" and keep cells whole. Also WBCs contaminating CTCs can raise the "noise" compared to "signal" and contribute CH findings #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @n8pennell: @LeciaSequist Have this planned in EA 5181 chemo radiation trial for stage 3 NSCLC and others too I’m sure! #lcsm
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: T3. We could apply the concept of “minimal residual disease” to the setting of Early Stage #LungCancer and Locally Advanced #LungCancer to identify individuals with #ctDNA, who can be selected for additional therapy #LCSM https://t.co/kBTdPDGJJh
Arpan Patel @ArpanAshokPatel
RT @LeciaSequist: T2: T2: Liquid bx (ctDNA) is commonly used in lung cancer clinics today to identify actionable mutations in advanced adeno and can be additive to tissue NGS. Here's a great example from @CharuAggarwalMD @Jbauml @CoreyLangerMD https://t.co/5UJmen6MlD #LCSM https://t.co/PB3O17BNzl
Christine Lovly @christine_lovly
@LeciaSequist @acmoorephd @lcsmchat @JFreemanDaily @oncologician @CharuAggarwalMD @LaurenByersMD @triparnasen @cbmeador Lots of work going on in the space of liquid biopsy for SCLC - mutations, methylation, CTC subtyping. Active area of research but not “prime time” in the clinic yet. Stay tuned. #LCSM
#LCSM Chat @lcsmchat
RT @LeciaSequist: @oncologician @acmoorephd @lcsmchat @JFreemanDaily @CharuAggarwalMD @LaurenByersMD @triparnasen @christine_lovly @cbmeador Depends on the method that you are using to collect CTCs. Some methods are "rough" and break apart the CTCs, spilling contents. Others are "gentle" and keep cells whole. Also WBCs contaminating CTCs can raise the "noise" compared to "signal" and contribute CH findings #LCSM
#LCSM Chat @lcsmchat
RT @n8pennell: @LeciaSequist Have this planned in EA 5181 chemo radiation trial for stage 3 NSCLC and others too I’m sure! #lcsm
Nirmal Raut @oncologician
RT @LeciaSequist: T3: T3: One of the clearest examples of ctDNA being used to assess MRD is by @max_diehn and team, who showed that detectable ctDNA after radiation for early stage NSCLC is a poor prognostic factor #LCSM https://t.co/1xhYDih97r
Lecia Sequist, MD, MPH @LeciaSequist
@AliyeBricker @lcsmchat yes, yes, yes 100%! This is a really key point for anyone ordering a liquid biopsy to remember! #LCSM
#LCSM Chat @lcsmchat
RT @AliyeBricker: @LeciaSequist @lcsmchat If a liquid biopsy does not show the presence of a new resistance mechanism (such as a gate keeper mutation or solvent front mutation) despite clear evidence of progression on imaging, is it worth pursuing a tissue biopsy from a site of disease progression? #LCSM
Dr. Amy C. Moore @acmoorephd
I've lost track of topics but would be remiss not to point out @GO2Foundation and ALCMI's "SPACEWALK" study, which uses remote consent + liquid Bx to look at ALK resistance mechanisms. First manuscript just published! @geoff_oxnard @DrMarkAwad #lcsm
Upstage Lung Cancer @UpstageLungCanc
RT @CharuAggarwalMD: T3. We could apply the concept of “minimal residual disease” to the setting of Early Stage #LungCancer and Locally Advanced #LungCancer to identify individuals with #ctDNA, who can be selected for additional therapy #LCSM https://t.co/kBTdPDGJJh
Upstage Lung Cancer @UpstageLungCanc
RT @acmoorephd: I've lost track of topics but would be remiss not to point out @GO2Foundation and ALCMI's "SPACEWALK" study, which uses remote consent + liquid Bx to look at ALK resistance mechanisms. First manuscript just published! @geoff_oxnard @DrMarkAwad #lcsm
#LCSM Chat @lcsmchat
RT @christine_lovly: @LeciaSequist @acmoorephd @lcsmchat @JFreemanDaily @oncologician @CharuAggarwalMD @LaurenByersMD @triparnasen @cbmeador Lots of work going on in the space of liquid biopsy for SCLC - mutations, methylation, CTC subtyping. Active area of research but not “prime time” in the clinic yet. Stay tuned. #LCSM
#LCSM Chat @lcsmchat
RT @LeciaSequist: @AliyeBricker @lcsmchat yes, yes, yes 100%! This is a really key point for anyone ordering a liquid biopsy to remember! #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
T3. Our colleagues @aparna1024 et al are already applying these strategies in the field of GI Oncology, where patients that are ctDNA positive are offered adjuvant chemotherapy #LCSM https://t.co/uODloajYyp
#LCSM Chat @lcsmchat
RT @acmoorephd: I've lost track of topics but would be remiss not to point out @GO2Foundation and ALCMI's "SPACEWALK" study, which uses remote consent + liquid Bx to look at ALK resistance mechanisms. First manuscript just published! @geoff_oxnard @DrMarkAwad #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
Excellent Initiative! #LCSM @GO2Foundation
Danielle Pardue @Actorielle
RT @acmoorephd: I've lost track of topics but would be remiss not to point out @GO2Foundation and ALCMI's "SPACEWALK" study, which uses remote consent + liquid Bx to look at ALK resistance mechanisms. First manuscript just published! @geoff_oxnard @DrMarkAwad #lcsm
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: T3. Our colleagues @aparna1024 et al are already applying these strategies in the field of GI Oncology, where patients that are ctDNA positive are offered adjuvant chemotherapy #LCSM https://t.co/uODloajYyp
Danielle Pardue @Actorielle
RT @CharuAggarwalMD: T3. Our colleagues @aparna1024 et al are already applying these strategies in the field of GI Oncology, where patients that are ctDNA positive are offered adjuvant chemotherapy #LCSM https://t.co/uODloajYyp
Janet Freeman-Daily @JFreemanDaily
@AliyeBricker @LeciaSequist @lcsmchat Liquid biopsy guidelines in #lungcancer acknowledge the possibility of false negatives. If the liquid bx is positive, then treat based on liquid bx results. If liquid bx is negative, try to test with tissue. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @AliyeBricker: @LeciaSequist @lcsmchat If a liquid biopsy does not show the presence of a new resistance mechanism (such as a gate keeper mutation or solvent front mutation) despite clear evidence of progression on imaging, is it worth pursuing a tissue biopsy from a site of disease progression? #LCSM
#LCSM Chat @lcsmchat
#lcsm
Lecia Sequist, MD, MPH @LeciaSequist
@MGHCancerCenter 👏
Nirmal Raut @oncologician
RT @christine_lovly: @LeciaSequist @acmoorephd @lcsmchat @JFreemanDaily @oncologician @CharuAggarwalMD @LaurenByersMD @triparnasen @cbmeador Lots of work going on in the space of liquid biopsy for SCLC - mutations, methylation, CTC subtyping. Active area of research but not “prime time” in the clinic yet. Stay tuned. #LCSM
Upstage Lung Cancer @UpstageLungCanc
RT @CharuAggarwalMD: T3. Our colleagues @aparna1024 et al are already applying these strategies in the field of GI Oncology, where patients that are ctDNA positive are offered adjuvant chemotherapy #LCSM https://t.co/uODloajYyp
Janet Freeman-Daily @JFreemanDaily
RT @christine_lovly: @LeciaSequist @acmoorephd @lcsmchat @JFreemanDaily @oncologician @CharuAggarwalMD @LaurenByersMD @triparnasen @cbmeador Lots of work going on in the space of liquid biopsy for SCLC - mutations, methylation, CTC subtyping. Active area of research but not “prime time” in the clinic yet. Stay tuned. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: @AliyeBricker @lcsmchat yes, yes, yes 100%! This is a really key point for anyone ordering a liquid biopsy to remember! #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @acmoorephd: I've lost track of topics but would be remiss not to point out @GO2Foundation and ALCMI's "SPACEWALK" study, which uses remote consent + liquid Bx to look at ALK resistance mechanisms. First manuscript just published! @geoff_oxnard @DrMarkAwad #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @AliyeBricker @LeciaSequist @lcsmchat Liquid biopsy guidelines in #lungcancer acknowledge the possibility of false negatives. If the liquid bx is positive, then treat based on liquid bx results. If liquid bx is negative, try to test with tissue. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: T3. Our colleagues @aparna1024 et al are already applying these strategies in the field of GI Oncology, where patients that are ctDNA positive are offered adjuvant chemotherapy #LCSM https://t.co/uODloajYyp
Nirmal Raut @oncologician
RT @LeciaSequist: T2: T2: One thing we aren't sure of yet is when/if/how to react to a resistance mechanism found on ctDNA in the absence of radiographic or symptomatic progression. Prospective trials are needed! #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: Excellent Initiative! #LCSM @GO2Foundation
Gia Sonata @RedGia
RT @TriageCancer: @JFreemanDaily @KAdvocate_LCAM @CharuAggarwalMD @LeciaSequist There are free resources about navigating health insurance, health insurance appeals, and other issues related to payment for various biomarker tests at our website: https://t.co/zY7CesHqJn and also https://t.co/5IxhJu4Y0S #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @lcsmchat: #lcsm
Ladi Akinboro @LadiAkinboro
RT @FDAOncology: FDA granted regular approval to lorlatinib (Lorbrena, Pfizer) for metastatic ALK+ non-small cell lung cancer. FDA also approved the Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems) as a companion diagnostic for lorlatinib. #LCSM #NSCLC https://t.co/gcQF0Fin70
Dr. Amy C. Moore @acmoorephd
RT @christine_lovly: @LeciaSequist @acmoorephd @lcsmchat @JFreemanDaily @oncologician @CharuAggarwalMD @LaurenByersMD @triparnasen @cbmeador Lots of work going on in the space of liquid biopsy for SCLC - mutations, methylation, CTC subtyping. Active area of research but not “prime time” in the clinic yet. Stay tuned. #LCSM
Janet Freeman-Daily @JFreemanDaily
#LCSM
#LCSM Chat @lcsmchat
#lcsm
Christian Rolfo @ChristianRolfo
@CharuAggarwalMD @aparna1024 In NSCLC studies like Mermaid will answer several questions about MRD tailoring adjuvant treatment. #lcsm @isliquidbiopsy https://t.co/hZnLIhyU1o
Nirmal Raut @oncologician
RT @JFreemanDaily: #LCSM
Dr. Amy C. Moore @acmoorephd
RT @JFreemanDaily: @AliyeBricker @LeciaSequist @lcsmchat Liquid biopsy guidelines in #lungcancer acknowledge the possibility of false negatives. If the liquid bx is positive, then treat based on liquid bx results. If liquid bx is negative, try to test with tissue. #lcsm
Lisa Briggs @livinglife82
@lcsmchat Many thanks #LCSM
Christian Rolfo @ChristianRolfo
#lcsm
NCI Cancer Stats @NCICancerStats
There were ~228,820 new cases of #LungCancer in the US last year. Use our Cancer Stat Facts sheet to learn more about this cancer: https://t.co/BVqvN4e1pm #LCSM https://t.co/mQXofmUlGZ
#LCSM Chat @lcsmchat
RT @ChristianRolfo: #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @ChristianRolfo: @CharuAggarwalMD @aparna1024 In NSCLC studies like Mermaid will answer several questions about MRD tailoring adjuvant treatment. #lcsm @isliquidbiopsy https://t.co/hZnLIhyU1o
#LCSM Chat @lcsmchat
RT @ChristianRolfo: @CharuAggarwalMD @aparna1024 In NSCLC studies like Mermaid will answer several questions about MRD tailoring adjuvant treatment. #lcsm @isliquidbiopsy https://t.co/hZnLIhyU1o
Nathan A. Pennell MD, PhD, FASCO @n8pennell
RT @ChristianRolfo: @CharuAggarwalMD @aparna1024 In NSCLC studies like Mermaid will answer several questions about MRD tailoring adjuvant treatment. #lcsm @isliquidbiopsy https://t.co/hZnLIhyU1o
Janet Freeman-Daily @JFreemanDaily
RT @ChristianRolfo: #lcsm
Upstage Lung Cancer @UpstageLungCanc
RT @ChristianRolfo: #lcsm
Dr. Amy C. Moore @acmoorephd
RT @ChristianRolfo: @CharuAggarwalMD @aparna1024 In NSCLC studies like Mermaid will answer several questions about MRD tailoring adjuvant treatment. #lcsm @isliquidbiopsy https://t.co/hZnLIhyU1o
Whetstine Lab @WhetstineLab
RT @bjork5: Hi friends, Dave Bjork here in Boston, host of the https://t.co/WePGnEdkmc #LCSM
Janet Freeman-Daily @JFreemanDaily
The tweets in tonight's #lcsm chat on liquid biopsies have been fast and furious! Lots to unpack. Don't be afraid to ask questions. If we don't answer yours during the chat, we'll try to answer it after.
Erika Hlavacek @ErikaHlavacek
I had innumerable brain mets and systemic progression & liquid biopsy showed nothing. Tissue saved the day. #lcsm
#LCSM Chat @lcsmchat
#lcsm
#LCSM Chat @lcsmchat
RT @ErikaHlavacek: I had innumerable brain mets and systemic progression & liquid biopsy showed nothing. Tissue saved the day. #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: The tweets in tonight's #lcsm chat on liquid biopsies have been fast and furious! Lots to unpack. Don't be afraid to ask questions. If we don't answer yours during the chat, we'll try to answer it after.
Upstage Lung Cancer @UpstageLungCanc
RT @JFreemanDaily: The tweets in tonight's #lcsm chat on liquid biopsies have been fast and furious! Lots to unpack. Don't be afraid to ask questions. If we don't answer yours during the chat, we'll try to answer it after.
Nathan A. Pennell MD, PhD, FASCO @n8pennell
RT @ErikaHlavacek: I had innumerable brain mets and systemic progression & liquid biopsy showed nothing. Tissue saved the day. #lcsm
Jill Feldman @jillfeldman4
RT @ErikaHlavacek: I had innumerable brain mets and systemic progression & liquid biopsy showed nothing. Tissue saved the day. #lcsm
Kristin Ito @KAdvocate_LCAM
@JFreemanDaily So grateful for this safe space to learn! #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@ErikaHlavacek Liquid biopsies rely on the amount of "shed" DNA into the bloodstream, therefore, it is important to always use tissue NGS in case of negatives #LCSM
Janet Freeman-Daily @JFreemanDaily
@LeciaSequist @CharuAggarwalMD @ChristianRolfo Does cfDNA cross the blood-brain barrier? Can #liquidbiopsy be used to detect cancer in the brain? #LCSM
Danielle Pardue @Actorielle
RT @KAdvocate_LCAM: @JFreemanDaily So grateful for this safe space to learn! #LCSM
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: @ErikaHlavacek Liquid biopsies rely on the amount of "shed" DNA into the bloodstream, therefore, it is important to always use tissue NGS in case of negatives #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @lcsmchat: #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @LeciaSequist @CharuAggarwalMD @ChristianRolfo Does cfDNA cross the blood-brain barrier? Can #liquidbiopsy be used to detect cancer in the brain? #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: @ErikaHlavacek Liquid biopsies rely on the amount of "shed" DNA into the bloodstream, therefore, it is important to always use tissue NGS in case of negatives #LCSM
Danielle Pardue @Actorielle
RT @ChristianRolfo: #lcsm
Janet Freeman-Daily @JFreemanDaily
I've been so fascinated with all the tweets that I'm having trouble keeping track of time! BAD moderator. Topic T4 is coming up … #lcsm
Dave Bjork @bjork5
#lcsm
Janet Freeman-Daily @JFreemanDaily
T4. How might liquid biopsy be used for early detection of cancer? #lcsm
Lecia Sequist, MD, MPH @LeciaSequist
@JFreemanDaily @CharuAggarwalMD @ChristianRolfo From a practical standpoint, ctDNA liquid biopsy isn't a reliable way to examine the genetics of CNS disease or CNS-only progression. Sometimes using a ctDNA assay in the CSF can be informative though, especially in the setting of LMD #LCSM
Christian Rolfo @ChristianRolfo
@DrSteveMartin @CharuAggarwalMD Unfortunately you’re completely right, outside US the price for get this technology it’s very expensive for patients and we need to make accesible worldwide 🌎. Testing it’s a must not a luxury #lcsm @isliquidbiopsy in several countries they started to cover small panels
Dr. Amy C. Moore @acmoorephd
@JFreemanDaily @lcsmchat Help, I can't keep up! #lcsm
Kristin Ito @KAdvocate_LCAM
RT @JFreemanDaily: T4. How might liquid biopsy be used for early detection of cancer? #lcsm
Janet Freeman-Daily @JFreemanDaily
#LCSM
Matthew Smeltzer @MattSmeltzer
T4. Liquid biopsy and LDCT in series or in parallel? #LCSM
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T4. How might liquid biopsy be used for early detection of cancer? #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
T4. In the future, we will be using liquid biopsy across the spectrum of #LungCancer management including screening #LCSM https://t.co/T69wFYfxdl
Lecia Sequist, MD, MPH @LeciaSequist
T4: Early detection! A passion of mine because we have the opportunity to make the biggest decrease in lung cancer deaths if we can improve our success at finding lung cancer at early stages, when cure is more likely #LCSM
#LCSM Chat @lcsmchat
RT @LeciaSequist: @JFreemanDaily @CharuAggarwalMD @ChristianRolfo From a practical standpoint, ctDNA liquid biopsy isn't a reliable way to examine the genetics of CNS disease or CNS-only progression. Sometimes using a ctDNA assay in the CSF can be informative though, especially in the setting of LMD #LCSM
#LCSM Chat @lcsmchat
RT @ChristianRolfo: @DrSteveMartin @CharuAggarwalMD Unfortunately you’re completely right, outside US the price for get this technology it’s very expensive for patients and we need to make accesible worldwide 🌎. Testing it’s a must not a luxury #lcsm @isliquidbiopsy in several countries they started to cover small panels
Danielle Pardue @Actorielle
RT @JFreemanDaily: T4. How might liquid biopsy be used for early detection of cancer? #lcsm
Nirmal Raut @oncologician
@ChristianRolfo @CharuAggarwalMD @aparna1024 @isliquidbiopsy #LCSM Arent we missing the oppurtunity here to create memory T cell by not using Neo adjuvant IO @FordePatrick
#LCSM Chat @lcsmchat
RT @JFreemanDaily: #LCSM
#LCSM Chat @lcsmchat
RT @LeciaSequist: T4: T4: Early detection! A passion of mine because we have the opportunity to make the biggest decrease in lung cancer deaths if we can improve our success at finding lung cancer at early stages, when cure is more likely #LCSM
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: T4. In the future, we will be using liquid biopsy across the spectrum of #LungCancer management including screening #LCSM https://t.co/T69wFYfxdl
#LCSM Chat @lcsmchat
RT @MattSmeltzer: T4. Liquid biopsy and LDCT in series or in parallel? #LCSM
Nathan A. Pennell MD, PhD, FASCO @n8pennell
RT @CharuAggarwalMD: T4. In the future, we will be using liquid biopsy across the spectrum of #LungCancer management including screening #LCSM https://t.co/T69wFYfxdl
Lisa Briggs @livinglife82
@JFreemanDaily T1: Are fusions more difficult to detect via #liquidbiopsy because they are more vulnerable/unstable and prone to damage with transportation etc? My understanding is that this can be a problem with tissue biopsies? #LCSM @lcsmchat
Upstage Lung Cancer @UpstageLungCanc
RT @JFreemanDaily: T4. How might liquid biopsy be used for early detection of cancer? #lcsm
Upstage Lung Cancer @UpstageLungCanc
RT @LeciaSequist: T4: T4: Early detection! A passion of mine because we have the opportunity to make the biggest decrease in lung cancer deaths if we can improve our success at finding lung cancer at early stages, when cure is more likely #LCSM
Kristin Ito @KAdvocate_LCAM
RT @ChristianRolfo: @DrSteveMartin @CharuAggarwalMD Unfortunately you’re completely right, outside US the price for get this technology it’s very expensive for patients and we need to make accesible worldwide 🌎. Testing it’s a must not a luxury #lcsm @isliquidbiopsy in several countries they started to cover small panels
Lecia Sequist, MD, MPH @LeciaSequist
T4: One type of test being developed by a few companies is a multicancer early detection (MCED) assay, where asymptomatic people over a certain age could get a single blood test to screen for multiple cancers at once #LCSM
Lecia Sequist, MD, MPH @LeciaSequist
T4: It's still early days for MCED tests, but we're getting an early idea of how these could work. For example, the DETECT-A study looked at the CancerSEEK assay in 10K women and found 26 cancers, 17 of which were early stage #LCSM https://t.co/klcy0LZ6Rs https://t.co/LwZXETCvP2
Lecia Sequist, MD, MPH @LeciaSequist
T4: Early detection by liquid biopsy is wonderful concept, but in practice is tricky b/c a) volume of tumor is much smaller compared to advanced cancers; b) signature of tumor is unknown. Very sensitive assays are required with careful bioinformatic interpretation #LCSM
Lecia Sequist, MD, MPH @LeciaSequist
T4: Another approach: focus on high risk pop's, like those doing LDCT screening. Screen-detected nodules (could be cancer or benign) pose a great dilemma. @max_diehn @AshAlizadeh @JakeChabon me and others worked w @SU2C on an ultrasensitive ctDNA assay for early detection #LCSM https://t.co/efqdlSS4Jc
#LCSM Chat @lcsmchat
RT @livinglife82: @JFreemanDaily T1: @JFreemanDaily T1: Are fusions more difficult to detect via #liquidbiopsy because they are more vulnerable/unstable and prone to damage with transportation etc? My understanding is that this can be a problem with tissue biopsies? #LCSM @lcsmchat
Danielle Pardue @Actorielle
RT @LeciaSequist: T4: T4: Early detection! A passion of mine because we have the opportunity to make the biggest decrease in lung cancer deaths if we can improve our success at finding lung cancer at early stages, when cure is more likely #LCSM
Danielle Pardue @Actorielle
RT @CharuAggarwalMD: T4. In the future, we will be using liquid biopsy across the spectrum of #LungCancer management including screening #LCSM https://t.co/T69wFYfxdl
Janet Freeman-Daily @JFreemanDaily
#LCSM
Upstage Lung Cancer @UpstageLungCanc
RT @CharuAggarwalMD: T4. In the future, we will be using liquid biopsy across the spectrum of #LungCancer management including screening #LCSM https://t.co/T69wFYfxdl
#LCSM Chat @lcsmchat
RT @LeciaSequist: T4: Another approach: T4: Another approach: focus on high risk pop's, like those doing LDCT screening. Screen-detected nodules (could be cancer or benign) pose a great dilemma. @max_diehn @AshAlizadeh @JakeChabon me and others worked w @SU2C on an ultrasensitive ctDNA assay for early detection #LCSM https://t.co/efqdlSS4Jc
#LCSM Chat @lcsmchat
RT @LeciaSequist: T4: T4: It's still early days for MCED tests, but we're getting an early idea of how these could work. For example, the DETECT-A study looked at the CancerSEEK assay in 10K women and found 26 cancers, 17 of which were early stage #LCSM https://t.co/klcy0LZ6Rs https://t.co/LwZXETCvP2
Nathan A. Pennell MD, PhD, FASCO @n8pennell
RT @LeciaSequist: T4: Another approach: T4: Another approach: focus on high risk pop's, like those doing LDCT screening. Screen-detected nodules (could be cancer or benign) pose a great dilemma. @max_diehn @AshAlizadeh @JakeChabon me and others worked w @SU2C on an ultrasensitive ctDNA assay for early detection #LCSM https://t.co/efqdlSS4Jc
b_hring_m @b_hring_m
RT @CharuAggarwalMD: T4. In the future, we will be using liquid biopsy across the spectrum of #LungCancer management including screening #LCSM https://t.co/T69wFYfxdl
kristen kimball @KimballKristen
Someday may screening for LC be as common as colonoscopies and mammograms! #LCSM
#LCSM Chat @lcsmchat
RT @LeciaSequist: T4: T4: Early detection by liquid biopsy is wonderful concept, but in practice is tricky b/c a) volume of tumor is much smaller compared to advanced cancers; b) signature of tumor is unknown. Very sensitive assays are required with careful bioinformatic interpretation #LCSM
Nirmal Raut @oncologician
RT @CharuAggarwalMD: T4. In the future, we will be using liquid biopsy across the spectrum of #LungCancer management including screening #LCSM https://t.co/T69wFYfxdl
Upstage Lung Cancer @UpstageLungCanc
RT @LeciaSequist: T4: Another approach: T4: Another approach: focus on high risk pop's, like those doing LDCT screening. Screen-detected nodules (could be cancer or benign) pose a great dilemma. @max_diehn @AshAlizadeh @JakeChabon me and others worked w @SU2C on an ultrasensitive ctDNA assay for early detection #LCSM https://t.co/efqdlSS4Jc
#LCSM Chat @lcsmchat
RT @LeciaSequist: T4: T4: One type of test being developed by a few companies is a multicancer early detection (MCED) assay, where asymptomatic people over a certain age could get a single blood test to screen for multiple cancers at once #LCSM
#LCSM Chat @lcsmchat
RT @JFreemanDaily: #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: @JFreemanDaily @CharuAggarwalMD @ChristianRolfo From a practical standpoint, ctDNA liquid biopsy isn't a reliable way to examine the genetics of CNS disease or CNS-only progression. Sometimes using a ctDNA assay in the CSF can be informative though, especially in the setting of LMD #LCSM
Upstage Lung Cancer @UpstageLungCanc
RT @LeciaSequist: T4: T4: It's still early days for MCED tests, but we're getting an early idea of how these could work. For example, the DETECT-A study looked at the CancerSEEK assay in 10K women and found 26 cancers, 17 of which were early stage #LCSM https://t.co/klcy0LZ6Rs https://t.co/LwZXETCvP2
#LCSM Chat @lcsmchat
RT @KimballKristen: Someday may screening for LC be as common as colonoscopies and mammograms! #LCSM
Nathan A. Pennell MD, PhD, FASCO @n8pennell
RT @LeciaSequist: T4: T4: Early detection by liquid biopsy is wonderful concept, but in practice is tricky b/c a) volume of tumor is much smaller compared to advanced cancers; b) signature of tumor is unknown. Very sensitive assays are required with careful bioinformatic interpretation #LCSM
Janet Freeman-Daily @JFreemanDaily
@acmoorephd @lcsmchat I know the feeling ... #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@n8pennell Yes! @JulienMazieres et al #LCSM https://t.co/uQFaA6dH2Z
Upstage Lung Cancer @UpstageLungCanc
RT @LeciaSequist: T4: T4: Early detection by liquid biopsy is wonderful concept, but in practice is tricky b/c a) volume of tumor is much smaller compared to advanced cancers; b) signature of tumor is unknown. Very sensitive assays are required with careful bioinformatic interpretation #LCSM
Upstage Lung Cancer @UpstageLungCanc
RT @LeciaSequist: T4: T4: One type of test being developed by a few companies is a multicancer early detection (MCED) assay, where asymptomatic people over a certain age could get a single blood test to screen for multiple cancers at once #LCSM
kristen kimball @KimballKristen
RT @CharuAggarwalMD: T4. In the future, we will be using liquid biopsy across the spectrum of #LungCancer management including screening #LCSM https://t.co/T69wFYfxdl
Danielle Pardue @Actorielle
RT @LeciaSequist: T4: Another approach: T4: Another approach: focus on high risk pop's, like those doing LDCT screening. Screen-detected nodules (could be cancer or benign) pose a great dilemma. @max_diehn @AshAlizadeh @JakeChabon me and others worked w @SU2C on an ultrasensitive ctDNA assay for early detection #LCSM https://t.co/efqdlSS4Jc
Janet Freeman-Daily @JFreemanDaily
RT @livinglife82: @JFreemanDaily T1: @JFreemanDaily T1: Are fusions more difficult to detect via #liquidbiopsy because they are more vulnerable/unstable and prone to damage with transportation etc? My understanding is that this can be a problem with tissue biopsies? #LCSM @lcsmchat
Danielle Pardue @Actorielle
RT @LeciaSequist: T4: T4: It's still early days for MCED tests, but we're getting an early idea of how these could work. For example, the DETECT-A study looked at the CancerSEEK assay in 10K women and found 26 cancers, 17 of which were early stage #LCSM https://t.co/klcy0LZ6Rs https://t.co/LwZXETCvP2
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: @n8pennell Yes! @JulienMazieres et al #LCSM https://t.co/uQFaA6dH2Z
Danielle Pardue @Actorielle
RT @LeciaSequist: T4: T4: Early detection by liquid biopsy is wonderful concept, but in practice is tricky b/c a) volume of tumor is much smaller compared to advanced cancers; b) signature of tumor is unknown. Very sensitive assays are required with careful bioinformatic interpretation #LCSM
Danielle Pardue @Actorielle
RT @LeciaSequist: T4: T4: One type of test being developed by a few companies is a multicancer early detection (MCED) assay, where asymptomatic people over a certain age could get a single blood test to screen for multiple cancers at once #LCSM
Ilene Kaminsky @ilenealizah
I’ve had one, they do work in some cases. Thankfully mine.
Danielle Pardue @Actorielle
RT @CharuAggarwalMD: @n8pennell Yes! @JulienMazieres et al #LCSM https://t.co/uQFaA6dH2Z
Upstage Lung Cancer @UpstageLungCanc
RT @CharuAggarwalMD: @n8pennell Yes! @JulienMazieres et al #LCSM https://t.co/uQFaA6dH2Z
Dave Bjork @bjork5
This! 👇 #lcsm
Jill Feldman @jillfeldman4
T4 Using liquid biopsy for early detection in #lungcancer is the HOLY GRAIL! #LCSM
Janet Freeman-Daily @JFreemanDaily
#LCSM
Erika Hlavacek @ErikaHlavacek
@ChristianRolfo @DrSteveMartin @CharuAggarwalMD @isliquidbiopsy We forgot how good we have it, and take our medical coverage for granted. I'm humbled hearing what happens elsewhere and very sad for my fellow pts. #lcsm
#LCSM Chat @lcsmchat
RT @jillfeldman4: T4 Using liquid biopsy for early detection in #lungcancer is the HOLY GRAIL! #LCSM
Lecia Sequist, MD, MPH @LeciaSequist
@MattSmeltzer Great question! IMO, depends on the qualities of your liquid biopsy platform. LBx done instead of/before LDCT would need excellent sensitivity. A test done after abnormal LDCT may prioritize specificity. Could be benefits to either approach, need the right tool for the job #LCSM https://t.co/gHusVfyIQw
Janet Freeman-Daily @JFreemanDaily
#LCSM
#LCSM Chat @lcsmchat
RT @JFreemanDaily: #LCSM
Nathan A. Pennell MD, PhD, FASCO @n8pennell
RT @CharuAggarwalMD: @n8pennell Yes! @JulienMazieres et al #LCSM https://t.co/uQFaA6dH2Z
#LCSM Chat @lcsmchat
RT @ErikaHlavacek: @ChristianRolfo @DrSteveMartin @CharuAggarwalMD @isliquidbiopsy We forgot how good we have it, and take our medical coverage for granted. I'm humbled hearing what happens elsewhere and very sad for my fellow pts. #lcsm
#LCSM Chat @lcsmchat
RT @LeciaSequist: @MattSmeltzer Great question! IMO, depends on the qualities of your liquid biopsy platform. LBx done instead of/before LDCT would need excellent sensitivity. A test done after abnormal LDCT may prioritize specificity. Could be benefits to either approach, need the right tool for the job #LCSM https://t.co/gHusVfyIQw
Guardant Health @GuardantHealth
RT @CharuAggarwalMD: Liquid biopsies are a valuable tool in the therapeutic management in #NSCLC. We now have 2 @FDAOncology approved assays for use in the clinic to maximize our ability to detect mutations @GuardantHealth @FoundationATCG #LCSM https://t.co/Z7NGwXy9yj
Janet Freeman-Daily @JFreemanDaily
Please remember to include #LCSM in all your tweets during #LCSM Chat so all the chat participants will see them.
Gia Sonata @RedGia
T4. #lcsm please see below. I forgot the tags ;)
kristen kimball @KimballKristen
RT @LeciaSequist: T4: T4: One type of test being developed by a few companies is a multicancer early detection (MCED) assay, where asymptomatic people over a certain age could get a single blood test to screen for multiple cancers at once #LCSM
#LCSM Chat @lcsmchat
RT @JFreemanDaily: #LCSM
Luis E Raez @LuisERaez1
This is one of the potential applications of liquid biopsy that needs to be explore! #LCSM @isliquidbiopsy
#LCSM Chat @lcsmchat
RT @JFreemanDaily: Please remember to include #LCSM in all your tweets during #LCSM Chat so all the chat participants will see them.
Venky @venkymd
RT @CharuAggarwalMD: T4. In the future, we will be using liquid biopsy across the spectrum of #LungCancer management including screening #LCSM https://t.co/T69wFYfxdl
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: T4: T4: Early detection! A passion of mine because we have the opportunity to make the biggest decrease in lung cancer deaths if we can improve our success at finding lung cancer at early stages, when cure is more likely #LCSM
Nirmal Raut @oncologician
@LeciaSequist Wondering if this will more applicable in Asian countries where the incidence of EGFR is ~40% #LCSM
Christian Rolfo @ChristianRolfo
@CharuAggarwalMD #lcsm including cancer interception, so to identify all the process are involved in cancer start. https://t.co/JZzlotz2Pu @MJOSESERRANO19 @CD_AACR @isliquidbiopsy https://t.co/zxLU9LzLgf
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: T4. In the future, we will be using liquid biopsy across the spectrum of #LungCancer management including screening #LCSM https://t.co/T69wFYfxdl
Monkey🙈🙉🙊 @Monkey26697239
RT @MDAndersonNews: An MD Anderson study has defined a previously unknown fourth type of small-cell lung cancer and offers new therapeutic strategies: https://t.co/K2Ur27eZxj @LaurenByersMD #LCSM #EndCancer
#LCSM Chat @lcsmchat
RT @RedGia: T4. #lcsm please see below. I forgot the tags ;)
Janet Freeman-Daily @JFreemanDaily
RT @MattSmeltzer: T4. Liquid biopsy and LDCT in series or in parallel? #LCSM
#LCSM Chat @lcsmchat
RT @LuisERaez1: This is one of the potential applications of liquid biopsy that needs to be explore! #LCSM @isliquidbiopsy
#LCSM Chat @lcsmchat
RT @oncologician: @LeciaSequist Wondering if this will more applicable in Asian countries where the incidence of EGFR is ~40% #LCSM
Lecia Sequist, MD, MPH @LeciaSequist
I hope that this assay (called Lung-CLiP) could be used in the future to help differentiate benign from cancerous lung nodules #LCSM @max_diehn
#LCSM Chat @lcsmchat
RT @ChristianRolfo: @CharuAggarwalMD #lcsm including cancer interception, so to identify all the process are involved in cancer start. https://t.co/JZzlotz2Pu @MJOSESERRANO19 @CD_AACR @isliquidbiopsy https://t.co/zxLU9LzLgf
Nirmal Raut @oncologician
RT @LeciaSequist: T4: T4: It's still early days for MCED tests, but we're getting an early idea of how these could work. For example, the DETECT-A study looked at the CancerSEEK assay in 10K women and found 26 cancers, 17 of which were early stage #LCSM https://t.co/klcy0LZ6Rs https://t.co/LwZXETCvP2
Upstage Lung Cancer @UpstageLungCanc
RT @JFreemanDaily: #LCSM
#LCSM Chat @lcsmchat
RT @LeciaSequist: I hope that this assay (called Lung-CLiP) could be used in the future to help differentiate benign from cancerous lung nodules #LCSM @max_diehn
Erika Hlavacek @ErikaHlavacek
You were in my STARS Program final presentation slides on Early Detection for your collaboration with SU2C and Lungevity. Exciting work, thank you! #lcsm
Nirmal Raut @oncologician
RT @acmoorephd: I've lost track of topics but would be remiss not to point out @GO2Foundation and ALCMI's "SPACEWALK" study, which uses remote consent + liquid Bx to look at ALK resistance mechanisms. First manuscript just published! @geoff_oxnard @DrMarkAwad #lcsm
Upstage Lung Cancer @UpstageLungCanc
RT @LeciaSequist: @MattSmeltzer Great question! IMO, depends on the qualities of your liquid biopsy platform. LBx done instead of/before LDCT would need excellent sensitivity. A test done after abnormal LDCT may prioritize specificity. Could be benefits to either approach, need the right tool for the job #LCSM https://t.co/gHusVfyIQw
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@RedGia I think that is a very difficult question to answer with a liquid bx. #LCSM
#LCSM Chat @lcsmchat
RT @ErikaHlavacek: You were in my STARS Program final presentation slides on Early Detection for your collaboration with SU2C and Lungevity. Exciting work, thank you! #lcsm
Janet Freeman-Daily @JFreemanDaily
@oncologician @ChristianRolfo @CharuAggarwalMD @aparna1024 @isliquidbiopsy @FordePatrick This chat is focused on #liquidbiopsy rather than treatment options. Hopefully one of the guests will have an opportunity to respond after the chat. Thanks for participating! #LCSM
Jill Feldman @jillfeldman4
RT @LeciaSequist: I hope that this assay (called Lung-CLiP) could be used in the future to help differentiate benign from cancerous lung nodules #LCSM @max_diehn
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: T4: Another approach: T4: Another approach: focus on high risk pop's, like those doing LDCT screening. Screen-detected nodules (could be cancer or benign) pose a great dilemma. @max_diehn @AshAlizadeh @JakeChabon me and others worked w @SU2C on an ultrasensitive ctDNA assay for early detection #LCSM https://t.co/efqdlSS4Jc
Danielle Pardue @Actorielle
RT @ChristianRolfo: @CharuAggarwalMD #lcsm including cancer interception, so to identify all the process are involved in cancer start. https://t.co/JZzlotz2Pu @MJOSESERRANO19 @CD_AACR @isliquidbiopsy https://t.co/zxLU9LzLgf
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: T4: T4: It's still early days for MCED tests, but we're getting an early idea of how these could work. For example, the DETECT-A study looked at the CancerSEEK assay in 10K women and found 26 cancers, 17 of which were early stage #LCSM https://t.co/klcy0LZ6Rs https://t.co/LwZXETCvP2
Erika Hlavacek @ErikaHlavacek
Future of lung cancer. How far we have come. #lcsm
Danielle Pardue @Actorielle
RT @JFreemanDaily: #LCSM
Danielle Pardue @Actorielle
RT @LeciaSequist: @MattSmeltzer Great question! IMO, depends on the qualities of your liquid biopsy platform. LBx done instead of/before LDCT would need excellent sensitivity. A test done after abnormal LDCT may prioritize specificity. Could be benefits to either approach, need the right tool for the job #LCSM https://t.co/gHusVfyIQw
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: T4: T4: Early detection by liquid biopsy is wonderful concept, but in practice is tricky b/c a) volume of tumor is much smaller compared to advanced cancers; b) signature of tumor is unknown. Very sensitive assays are required with careful bioinformatic interpretation #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: T4: T4: One type of test being developed by a few companies is a multicancer early detection (MCED) assay, where asymptomatic people over a certain age could get a single blood test to screen for multiple cancers at once #LCSM
Dr. Amy C. Moore @acmoorephd
RT @JFreemanDaily: #LCSM
Matthew Smeltzer @MattSmeltzer
RT @LeciaSequist: @MattSmeltzer Great question! IMO, depends on the qualities of your liquid biopsy platform. LBx done instead of/before LDCT would need excellent sensitivity. A test done after abnormal LDCT may prioritize specificity. Could be benefits to either approach, need the right tool for the job #LCSM https://t.co/gHusVfyIQw
Danielle Pardue @Actorielle
RT @jillfeldman4: T4 Using liquid biopsy for early detection in #lungcancer is the HOLY GRAIL! #LCSM
Luis E Raez @LuisERaez1
T1. Agree, however there is a lot to explore with cfRNA and exosomal RNA that can provide valuable information too, more research is needed #LCSM @isliquidbiopsy
Janet Freeman-Daily @JFreemanDaily
RT @KimballKristen: Someday may screening for LC be as common as colonoscopies and mammograms! #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: @n8pennell Yes! @JulienMazieres et al #LCSM https://t.co/uQFaA6dH2Z
#LCSM Chat @lcsmchat
RT @LuisERaez1: T1. Agree, however there is a lot to explore with cfRNA and exosomal RNA that can provide valuable information too, more research is needed #LCSM @isliquidbiopsy
Lisa Briggs @livinglife82
Sounds optimistic, however given the number of variables determining the outcome, perhaps there’s a role for #liquidbiopsies to confirm uncertainties detected through scans via #lungcancer #screening programs until sensitivity & precision improves? #lcsm @lcsmchat
Janet Freeman-Daily @JFreemanDaily
RT @jillfeldman4: T4 Using liquid biopsy for early detection in #lungcancer is the HOLY GRAIL! #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @ErikaHlavacek: @ChristianRolfo @DrSteveMartin @CharuAggarwalMD @isliquidbiopsy We forgot how good we have it, and take our medical coverage for granted. I'm humbled hearing what happens elsewhere and very sad for my fellow pts. #lcsm
Gia Sonata @RedGia
@CharuAggarwalMD Thanks. Worth a shot! #lcsm
#LCSM Chat @lcsmchat
RT @livinglife82: Sounds optimistic, however given the number of variables determining the outcome, perhaps there’s a role for #liquidbiopsies to confirm uncertainties detected through scans via #lungcancer #screening programs until sensitivity & precision improves? #lcsm @lcsmchat
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: @MattSmeltzer Great question! IMO, depends on the qualities of your liquid biopsy platform. LBx done instead of/before LDCT would need excellent sensitivity. A test done after abnormal LDCT may prioritize specificity. Could be benefits to either approach, need the right tool for the job #LCSM https://t.co/gHusVfyIQw
Jill Feldman @jillfeldman4
RT @CharuAggarwalMD: T4. In the future, we will be using liquid biopsy across the spectrum of #LungCancer management including screening #LCSM https://t.co/T69wFYfxdl
Janet Freeman-Daily @JFreemanDaily
RT @RedGia: T4. #lcsm please see below. I forgot the tags ;)
Erika Hlavacek @ErikaHlavacek
RT @LeciaSequist: T4: Another approach: T4: Another approach: focus on high risk pop's, like those doing LDCT screening. Screen-detected nodules (could be cancer or benign) pose a great dilemma. @max_diehn @AshAlizadeh @JakeChabon me and others worked w @SU2C on an ultrasensitive ctDNA assay for early detection #LCSM https://t.co/efqdlSS4Jc
Lecia Sequist, MD, MPH @LeciaSequist
@livinglife82 @lcsmchat I agree this is a really good setting for liquid biopsies to start 👍 #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @LuisERaez1: This is one of the potential applications of liquid biopsy that needs to be explore! #LCSM @isliquidbiopsy
Jill Feldman @jillfeldman4
RT @LuisERaez1: This is one of the potential applications of liquid biopsy that needs to be explore! #LCSM @isliquidbiopsy
Hari B. Keshava @hari_keshava
RT @jillfeldman4: T4 Using liquid biopsy for early detection in #lungcancer is the HOLY GRAIL! #LCSM
Dr. Amy C. Moore @acmoorephd
T4. I would say @GO2Foundation is very motivated to leverage our Centers of Excellence, including sites focused on best practices for LDCT screening, and couple that with ALCMI's capabilities in remote studies and liquid Bx to push the envelope on early #cancer detection. #lcsm
Janet Freeman-Daily @JFreemanDaily
@RedGia Please correct me if I'm wrong, but at present, we can't tell if cfDNA comes from a living cell or a cell that died and is breaking down, correct? #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
We have successfully incorporated plasma NGS into the clinical management of #NSCLC @NatRevClinOncol https://t.co/k7wiH2OjRw @geoff_oxnard @ChristianRolfo @drgandara @lmsholl #LCSM https://t.co/w3pMKInDq4
Janet Freeman-Daily @JFreemanDaily
RT @oncologician: @LeciaSequist Wondering if this will more applicable in Asian countries where the incidence of EGFR is ~40% #LCSM
#LCSM Chat @lcsmchat
RT @acmoorephd: T4. I would say @GO2Foundation is very motivated to leverage our Centers of Excellence, including sites focused on best practices for LDCT screening, and couple that with ALCMI's capabilities in remote studies and liquid Bx to push the envelope on early #cancer detection. #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @RedGia Please correct me if I'm wrong, but at present, we can't tell if cfDNA comes from a living cell or a cell that died and is breaking down, correct? #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @ChristianRolfo: @CharuAggarwalMD #lcsm including cancer interception, so to identify all the process are involved in cancer start. https://t.co/JZzlotz2Pu @MJOSESERRANO19 @CD_AACR @isliquidbiopsy https://t.co/zxLU9LzLgf
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: We have successfully incorporated plasma NGS into the clinical management of #NSCLC @NatRevClinOncol https://t.co/k7wiH2OjRw @geoff_oxnard @ChristianRolfo @drgandara @lmsholl #LCSM https://t.co/w3pMKInDq4
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: I hope that this assay (called Lung-CLiP) could be used in the future to help differentiate benign from cancerous lung nodules #LCSM @max_diehn
Janet Freeman-Daily @JFreemanDaily
RT @ErikaHlavacek: You were in my STARS Program final presentation slides on Early Detection for your collaboration with SU2C and Lungevity. Exciting work, thank you! #lcsm
Erika Hlavacek @ErikaHlavacek
Dream: Breast mammogram & lung cancer screening given together! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: @RedGia I think that is a very difficult question to answer with a liquid bx. #LCSM
Nirmal Raut @oncologician
RT @LeciaSequist: @JFreemanDaily @CharuAggarwalMD @ChristianRolfo From a practical standpoint, ctDNA liquid biopsy isn't a reliable way to examine the genetics of CNS disease or CNS-only progression. Sometimes using a ctDNA assay in the CSF can be informative though, especially in the setting of LMD #LCSM
Upstage Lung Cancer @UpstageLungCanc
Always a pleasure to learn from the work our friends at @GO2Foundation are doing! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @ErikaHlavacek: Future of lung cancer. How far we have come. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @LuisERaez1: T1. Agree, however there is a lot to explore with cfRNA and exosomal RNA that can provide valuable information too, more research is needed #LCSM @isliquidbiopsy
Nathan A. Pennell MD, PhD, FASCO @n8pennell
RT @CharuAggarwalMD: We have successfully incorporated plasma NGS into the clinical management of #NSCLC @NatRevClinOncol https://t.co/k7wiH2OjRw @geoff_oxnard @ChristianRolfo @drgandara @lmsholl #LCSM https://t.co/w3pMKInDq4
Lisa Briggs @livinglife82
Wouldn’t this be nice? Imagine a future where diagnostic tests are highly sensitive and specific, readily available, easily accessible, less invasive and able to be used across the spectrum of #lungcancer care. #lcsm @lcsmchat
Gia Sonata @RedGia
RT @ErikaHlavacek: Dream: Dream: Breast mammogram & lung cancer screening given together! #lcsm
Danielle Pardue @Actorielle
RT @livinglife82: Wouldn’t this be nice? Imagine a future where diagnostic tests are highly sensitive and specific, readily available, easily accessible, less invasive and able to be used across the spectrum of #lungcancer care. #lcsm @lcsmchat
Janet Freeman-Daily @JFreemanDaily
RT @livinglife82: Sounds optimistic, however given the number of variables determining the outcome, perhaps there’s a role for #liquidbiopsies to confirm uncertainties detected through scans via #lungcancer #screening programs until sensitivity & precision improves? #lcsm @lcsmchat
Danielle Pardue @Actorielle
RT @ErikaHlavacek: Dream: Dream: Breast mammogram & lung cancer screening given together! #lcsm
Lecia Sequist, MD, MPH @LeciaSequist
@JFreemanDaily @RedGia Not by looking at the DNA. There is the potential for some liquid biopsies to tell us more about function and current activity in the body, but these are far from the clinic. I'm thinking of RNA, proteomics, even exosomes. #LCSM
Danielle Pardue @Actorielle
RT @CharuAggarwalMD: We have successfully incorporated plasma NGS into the clinical management of #NSCLC @NatRevClinOncol https://t.co/k7wiH2OjRw @geoff_oxnard @ChristianRolfo @drgandara @lmsholl #LCSM https://t.co/w3pMKInDq4
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: @livinglife82 @lcsmchat I agree this is a really good setting for liquid biopsies to start 👍 #LCSM
Christian Rolfo @ChristianRolfo
#lcsm @LeciaSequist @CharuAggarwalMD @JFreemanDaily an important aspect is also the interpretation of LB results. Molecular Tumor Boards are a great tool to avoid problems in results interpretation. Multidisciplinary knowledge is needed .
#LCSM Chat @lcsmchat
RT @ErikaHlavacek: Dream: Dream: Breast mammogram & lung cancer screening given together! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @acmoorephd: T4. I would say @GO2Foundation is very motivated to leverage our Centers of Excellence, including sites focused on best practices for LDCT screening, and couple that with ALCMI's capabilities in remote studies and liquid Bx to push the envelope on early #cancer detection. #lcsm
#LCSM Chat @lcsmchat
RT @livinglife82: Wouldn’t this be nice? Imagine a future where diagnostic tests are highly sensitive and specific, readily available, easily accessible, less invasive and able to be used across the spectrum of #lungcancer care. #lcsm @lcsmchat
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: We have successfully incorporated plasma NGS into the clinical management of #NSCLC @NatRevClinOncol https://t.co/k7wiH2OjRw @geoff_oxnard @ChristianRolfo @drgandara @lmsholl #LCSM https://t.co/w3pMKInDq4
#LCSM Chat @lcsmchat
RT @LeciaSequist: @JFreemanDaily @RedGia Not by looking at the DNA. There is the potential for some liquid biopsies to tell us more about function and current activity in the body, but these are far from the clinic. I'm thinking of RNA, proteomics, even exosomes. #LCSM
#LCSM Chat @lcsmchat
RT @ChristianRolfo: #lcsm @LeciaSequist @CharuAggarwalMD @JFreemanDaily an important aspect is also the interpretation of LB results. Molecular Tumor Boards are a great tool to avoid problems in results interpretation. Multidisciplinary knowledge is needed .
Janet Freeman-Daily @JFreemanDaily
RT @ErikaHlavacek: Dream: Dream: Breast mammogram & lung cancer screening given together! #lcsm
Gia Sonata @RedGia
@livinglife82 @lcsmchat You had me at "less invasive" #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @UpstageLungCanc: Always a pleasure to learn from the work our friends at @GO2Foundation are doing! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @livinglife82: Wouldn’t this be nice? Imagine a future where diagnostic tests are highly sensitive and specific, readily available, easily accessible, less invasive and able to be used across the spectrum of #lungcancer care. #lcsm @lcsmchat
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: @JFreemanDaily @RedGia Not by looking at the DNA. There is the potential for some liquid biopsies to tell us more about function and current activity in the body, but these are far from the clinic. I'm thinking of RNA, proteomics, even exosomes. #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
Guidelines from @IASLC on #Plasma #NGS are being updated, and coming out soon! @ChristianRolfo @t_mitsudomi @HwakeleeMD #LCSM
Lecia Sequist, MD, MPH @LeciaSequist
Liquid bx's are most useful today for genotyping advanced lung cancers and in research settings, but I anticipate more clinical uses over time: prognosis, choosing therapies, early detection, drug development, and more! #ResearchMatters #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @ChristianRolfo: #lcsm @LeciaSequist @CharuAggarwalMD @JFreemanDaily an important aspect is also the interpretation of LB results. Molecular Tumor Boards are a great tool to avoid problems in results interpretation. Multidisciplinary knowledge is needed .
Janet Freeman-Daily @JFreemanDaily
RT @RedGia: @livinglife82 @lcsmchat You had me at "less invasive" #lcsm
Nirmal Raut @oncologician
RT @ErikaHlavacek: Future of lung cancer. How far we have come. #lcsm
Christian Rolfo @ChristianRolfo
RT @CharuAggarwalMD: Guidelines from @IASLC on #Plasma #NGS are being updated, and coming out soon! @ChristianRolfo @t_mitsudomi @HwakeleeMD #LCSM
Janet Freeman-Daily @JFreemanDaily
We’re in our final minutes - closing thoughts? #lcsm
Gia Sonata @RedGia
@LeciaSequist @JFreemanDaily Thank you both for the add'l info. #lcsm
#LCSM Chat @lcsmchat
RT @RedGia: @livinglife82 @lcsmchat You had me at "less invasive" #lcsm
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: Guidelines from @IASLC on #Plasma #NGS are being updated, and coming out soon! @ChristianRolfo @t_mitsudomi @HwakeleeMD #LCSM
#LCSM Chat @lcsmchat
RT @LeciaSequist: Liquid bx's are most useful today for genotyping advanced lung cancers and in research settings, but I anticipate more clinical uses over time: prognosis, choosing therapies, early detection, drug development, and more! #ResearchMatters #LCSM
#LCSM Chat @lcsmchat
RT @JFreemanDaily: We’re in our final minutes - closing thoughts? #lcsm
Gia Sonata @RedGia
RT @LeciaSequist: Liquid bx's are most useful today for genotyping advanced lung cancers and in research settings, but I anticipate more clinical uses over time: prognosis, choosing therapies, early detection, drug development, and more! #ResearchMatters #LCSM
Live.Breathe.Survive @LBSShow
RT @LUNGevity: Drug Approval Alert: Drug Approval Alert: The FDA has expanded the indication for lorlatinib to include the front-line treatment of patients with ALK+ metastatic #NSCLC: https://t.co/V6Xf9KabGG #LCSM
Christian Rolfo @ChristianRolfo
We hope we will see soon published! #lcsm great team of experts from @IASLC @drgandara
#LCSM Chat @lcsmchat
RT @ChristianRolfo: We hope we will see soon published! #lcsm great team of experts from @IASLC @drgandara
Anne Ireland, DNP, RN, AOCN, CENP @ONSAIreland
Proud to be part of open notes @cityofhope
Upstage Lung Cancer @UpstageLungCanc
RT @LeciaSequist: Liquid bx's are most useful today for genotyping advanced lung cancers and in research settings, but I anticipate more clinical uses over time: prognosis, choosing therapies, early detection, drug development, and more! #ResearchMatters #LCSM
Upstage Lung Cancer @UpstageLungCanc
RT @CharuAggarwalMD: Guidelines from @IASLC on #Plasma #NGS are being updated, and coming out soon! @ChristianRolfo @t_mitsudomi @HwakeleeMD #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@JFreemanDaily Thank you for the invitation to hang with the awesome #LCSM crew!
Upstage Lung Cancer @UpstageLungCanc
RT @livinglife82: Wouldn’t this be nice? Imagine a future where diagnostic tests are highly sensitive and specific, readily available, easily accessible, less invasive and able to be used across the spectrum of #lungcancer care. #lcsm @lcsmchat
Dave Bjork @bjork5
Thank you @LeciaSequist and @CharuAggarwalMD for your commitment to lung cancer patients & reseach #LCSM #liquidbiopsy #PrecisionMedicine
#LCSM Chat @lcsmchat
Many thanks to our rockstars @JFreemanDaily @LeciaSequist @CharuAggarwalMD for their invaluable work on this chat. #LCSM
Lecia Sequist, MD, MPH @LeciaSequist
@CharuAggarwalMD @JFreemanDaily This chat was so much fun - thank you #LCSM
Nirmal Raut @oncologician
@livinglife82 @lcsmchat And Utopian if affordable too #lcsm
Dr. Amy C. Moore @acmoorephd
@JFreemanDaily @lcsmchat Only that I am so thankful there are so many smart people working on this! WOW. #lcsm
Kristin Ito @KAdvocate_LCAM
Definitely going to have to take time to go back through all of the resources shared tonight! I appreciate you all! #LCSM
Upstage Lung Cancer @UpstageLungCanc
Thank you so much to the fantastic moderators and distinguished guests and educators! This chat is always phenomenal. #lcsm
Janet Freeman-Daily @JFreemanDaily
A HUGE thank you to our #LCSM Chat special guests tonight @CharuAggarwalMD and @LeciaSequist for a flood of informative, easy to understand tweets! I will definitely be creating a @wakelet summary of this chat! I learned SO much!
#LCSM Chat @lcsmchat
RT @JFreemanDaily: A HUGE thank you to our #LCSM Chat special guests tonight @CharuAggarwalMD and @LeciaSequist for a flood of informative, easy to understand tweets! I will definitely be creating a @wakelet summary of this chat! I learned SO much!
Danielle Pardue @Actorielle
@KAdvocate_LCAM Saaaaaame! 🙏🙌💚 #lcsm
Denise Cutlip @dennycee
Thank you for a highly informative chat #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: Guidelines from @IASLC on #Plasma #NGS are being updated, and coming out soon! @ChristianRolfo @t_mitsudomi @HwakeleeMD #LCSM
Danielle Pardue @Actorielle
RT @lcsmchat: Many thanks to our rockstars @JFreemanDaily @LeciaSequist @CharuAggarwalMD for their invaluable work on this chat. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: Liquid bx's are most useful today for genotyping advanced lung cancers and in research settings, but I anticipate more clinical uses over time: prognosis, choosing therapies, early detection, drug development, and more! #ResearchMatters #LCSM
Nathan A. Pennell MD, PhD, FASCO @n8pennell
My closing thoughts are that this has been one of the best #lcsm chats ever, such a great job by @LeciaSequist and @CharuAggarwalMD (and @JFreemanDaily)!
Janet Freeman-Daily @JFreemanDaily
RT @ChristianRolfo: We hope we will see soon published! #lcsm great team of experts from @IASLC @drgandara
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: @JFreemanDaily Thank you for the invitation to hang with the awesome #LCSM crew!
Janet Freeman-Daily @JFreemanDaily
RT @bjork5: Thank you @LeciaSequist and @CharuAggarwalMD for your commitment to lung cancer patients & reseach #LCSM #liquidbiopsy #PrecisionMedicine
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@JFreemanDaily @LeciaSequist @wakelet It was awesome! #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @lcsmchat: Many thanks to our rockstars @JFreemanDaily @LeciaSequist @CharuAggarwalMD for their invaluable work on this chat. #LCSM
Danielle Pardue @Actorielle
Thank you #lcsm team! You all are the BEST! What a mind-blowing chat! 💚
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: @CharuAggarwalMD @JFreemanDaily This chat was so much fun - thank you #LCSM
Danielle Pardue @Actorielle
RT @JFreemanDaily: A HUGE thank you to our #LCSM Chat special guests tonight @CharuAggarwalMD and @LeciaSequist for a flood of informative, easy to understand tweets! I will definitely be creating a @wakelet summary of this chat! I learned SO much!
Janet Freeman-Daily @JFreemanDaily
RT @acmoorephd: @JFreemanDaily @lcsmchat Only that I am so thankful there are so many smart people working on this! WOW. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @KAdvocate_LCAM: Definitely going to have to take time to go back through all of the resources shared tonight! I appreciate you all! #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @UpstageLungCanc: Thank you so much to the fantastic moderators and distinguished guests and educators! This chat is always phenomenal. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @Actorielle: @KAdvocate_LCAM Saaaaaame! 🙏🙌💚 #lcsm